CNS, Nerve & Mental Health

Pregabalin is an analogue of gamma-aminobutyric acid (GABA) that acts as a potent ligand at the alpha-2-delta auxiliary subunit of presynaptic voltage-gated calcium channels in the central nervous system. By reducing calcium influx into hyper-excited neurons, it curbs the pathological release of glutamate, substance P, and calcitonin gene-related peptide. Indicated for neuropathic pain associated with diabetic peripheral neuropathy, post-herpetic neuralgia, fibromyalgia, generalized anxiety disorder (GAD), and adjunctive therapy for partial-onset seizures.

Alprazolam is a short-acting, high-potency triazolobenzodiazepine. It enhances the binding affinity of the major inhibitory neurotransmitter GABA to GABAA receptors, opening neuronal chloride ion channels, hyperpolarizing membranes, and producing rapid anxiolytic, sedative, muscle-relaxant, and anticonvulsant effects. Indicated for acute management of generalized anxiety disorder (GAD) and panic disorder with or without agoraphobia.

Alprazolam is a short-acting, high-potency triazolobenzodiazepine. It enhances the binding affinity of the major inhibitory neurotransmitter GABA to GABAA receptors, opening neuronal chloride ion channels, hyperpolarizing membranes, and producing rapid anxiolytic, sedative, muscle-relaxant, and anticonvulsant effects. Indicated for acute management of generalized anxiety disorder (GAD) and panic disorder with or without agoraphobia.

Betahistine is a synthetic structural histamine analogue that acts as a strong antagonist at histamine H3 receptors and a weak agonist at histamine H1 receptors. By blocking H3 autoreceptors in the inner ear and vestibular nuclei, it enhances local histamine release, dilating precapillary sphincters in the stria vascularis and microvasculature of the labyrinth, thereby reducing endolymphatic hydrops pressure. Indicated for Meniere's disease (characterized by the triad of vertigo, tinnitus, and sensorineural hearing loss) and symptomatic vestibular vertigo.

Carbamazepine is an iminostilbene dibenzazepine antiepileptic on the WHO Model List of Essential Medicines. It voltage- and use-dependently blocks neuronal voltage-gated sodium channels, preventing repetitive neuronal firing and inhibiting spread of seizure discharges. It is the gold-standard first-line agent for trigeminal neuralgia. Indicated for focal (partial) seizures, generalized tonic-clonic seizures, trigeminal neuralgia, and acute mania/bipolar maintenance.

Clonazepam is a long-acting benzodiazepine with potent anticonvulsant, muscle-relaxant, and anxiolytic actions on the WHO Model List of Essential Medicines. It allosterically modulates GABAA receptors, increasing frequency of chloride channel opening and dampening epileptic foci in the cortex and limbic system. Indicated for panic disorder with or without agoraphobia, Lennox-Gastaut syndrome, myoclonic and akinetic seizures, and absence seizures refractory to succinimides.

Diazepam is a prototype long-acting 1,4-benzodiazepine on the WHO Model List of Essential Medicines. It binds to the GABAA receptor complex in the limbic system, thalamus, and hypothalamus, facilitating GABA-mediated inhibitory neurotransmission. Possesses an active desmethyldiazepam metabolite with a prolonged elimination half-life (up to 100 hours). Indicated for management of anxiety disorders, acute alcohol withdrawal syndrome (delirium tremens), skeletal muscle spasm, and status epilepticus.

Escitalopram is the therapeutically active S-enantiomer of citalopram and the most selective serotonin reuptake inhibitor (SSRI) available. It binds allosterically to the primary site of the human serotonin transporter (SERT), potently inhibiting serotonin reuptake into presynaptic terminals without appreciable affinity for dopamine or norepinephrine transporters or cholinergic/histaminergic receptors. Indicated for major depressive disorder (MDD) and generalized anxiety disorder (GAD).

Escitalopram is the therapeutically active S-enantiomer of citalopram and the most selective serotonin reuptake inhibitor (SSRI) available. It binds allosterically to the primary site of the human serotonin transporter (SERT), potently inhibiting serotonin reuptake into presynaptic terminals without appreciable affinity for dopamine or norepinephrine transporters or cholinergic/histaminergic receptors. Indicated for major depressive disorder (MDD) and generalized anxiety disorder (GAD).

Flunarizine is a difluorinated piperazine derivative that acts as a selective, long-acting calcium channel blocker with additional antihistaminic, dopamine D2-blocking, and antiserotonergic actions. It prevents cellular calcium overload under ischemic and hyper-excitable conditions in cerebral neurons without altering normal myocardial or vascular tone. Indicated for migraine prophylaxis in patients with frequent severe attacks, vestibular vertigo, and refractory partial seizures (adjunct).

Flunarizine is a difluorinated piperazine derivative that acts as a selective, long-acting calcium channel blocker with additional antihistaminic, dopamine D2-blocking, and antiserotonergic actions. It prevents cellular calcium overload under ischemic and hyper-excitable conditions in cerebral neurons without altering normal myocardial or vascular tone. Indicated for migraine prophylaxis in patients with frequent severe attacks, vestibular vertigo, and refractory partial seizures (adjunct).

Fluoxetine Hydrochloride is a prototype selective serotonin reuptake inhibitor (SSRI) on the WHO Model List of Essential Medicines. It blocks the presynaptic serotonin transporter (SERT) and possesses a long elimination half-life (1-3 days for parent drug, 7-15 days for active norfluoxetine), providing a built-in buffer against abrupt discontinuation syndrome. Also displays mild 5-HT2C antagonism, contributing to energizing/activating effects. Indicated for major depressive disorder, obsessive-compulsive disorder (OCD), bulimia nervosa, and panic disorder.

Methyl Ergometrine Tablets 0.125 mg is an evidence-based neuropsychiatric and central nervous system formulation. It acts by modulating neuronal neurotransmission, receptor kinetics, or ion channel conductance to manage neurological and mental health disorders.

Phenytoin is a classic hydantoin antiepileptic on the WHO Model List of Essential Medicines. It voltage- and use-dependently promotes sodium channel inactivation, stabilizing neuronal membranes and limiting the spread of seizure activity from epileptic foci. Exhibits non-linear (Michaelis-Menten) saturation pharmacokinetics, where small dose increases can produce disproportionate, toxic rises in plasma concentrations. Indicated for tonic-clonic (grand mal) seizures, focal seizures, and prevention/treatment of seizures following neurosurgery.

Prochlorperazine is a piperazine phenothiazine dopamine D2 antagonist with powerful antiemetic and vestibular-suppressant properties on the WHO Model List of Essential Medicines. It blocks D2 receptors in the chemoreceptor trigger zone (CTZ) of the medulla oblongata and vestibular nuclei, relieving vertigo and suppressing vomiting. Indicated for severe nausea and vomiting, vertigo associated with Meniere's disease or labyrinthitis, and acute migraine attacks.

Bupivacaine Hydrochloride is a long-acting amino-amide local and regional anesthetic on the WHO Model List of Essential Medicines. It blocks the generation and conduction of nerve impulses by reversibly binding and inhibiting voltage-gated sodium channels in the neuronal cell membrane. Features high lipid solubility and a prolonged duration of action (up to 3-6 hours). Indicated for spinal anesthesia, epidural block, peripheral nerve blocks, and post-operative infiltration analgesia.

Lignocaine (Lidocaine) Hydrochloride is the gold-standard amino-amide local anesthetic and Class Ib antiarrhythmic agent on the WHO Model List of Essential Medicines. It reversibly blocks voltage-gated sodium channels in neuronal cell membranes, stopping the generation and propagation of pain signals. When combined with Adrenaline (Epinephrine 1:80,000), localized vasoconstriction reduces surgical bleeding, slows systemic anesthetic absorption, and doubles the duration of local anesthesia. Indicated for infiltration anesthesia, regional nerve blocks, epidural anesthesia, and treatment of acute ventricular arrhythmias.

Lignocaine (Lidocaine) Hydrochloride is the gold-standard amino-amide local anesthetic and Class Ib antiarrhythmic agent on the WHO Model List of Essential Medicines. It reversibly blocks voltage-gated sodium channels in neuronal cell membranes, stopping the generation and propagation of pain signals. When combined with Adrenaline (Epinephrine 1:80,000), localized vasoconstriction reduces surgical bleeding, slows systemic anesthetic absorption, and doubles the duration of local anesthesia. Indicated for infiltration anesthesia, regional nerve blocks, epidural anesthesia, and treatment of acute ventricular arrhythmias.

Propofol is an ultra-short-acting alkylphenol intravenous general anesthetic on the WHO Model List of Essential Medicines. It acts by positive allosteric modulation of GABAA receptors, slowing channel closing time and potentiating GABA-mediated inhibitory synaptic currents, while inhibiting NMDA receptors. Features exceptionally rapid onset (around 30 seconds) and fast recovery without residual "hangover." Indicated for induction and maintenance of general anesthesia, sedation for surgical/diagnostic procedures, and sedation of mechanically ventilated ICU adults.

Levetiracetam is a pyrrolidone derivative second-generation antiepileptic on the WHO Model List of Essential Medicines. It exhibits a unique mechanism of action, binding stereoselectively to synaptic vesicle protein 2A (SV2A) in presynaptic terminals, modulating exocytosis and restraining pathological vesicle release of excitatory neurotransmitters without affecting normal neurotransmission. Demonstrates near 100% oral bioavailability and minimal hepatic CYP450 metabolism. Indicated as monotherapy and adjunctive therapy for focal seizures, myoclonic seizures in juvenile myoclonic epilepsy, and primary generalized tonic-clonic seizures.

Pregabalin is an analogue of gamma-aminobutyric acid (GABA) that acts as a potent ligand at the alpha-2-delta auxiliary subunit of presynaptic voltage-gated calcium channels in the central nervous system. By reducing calcium influx into hyper-excited neurons, it curbs the pathological release of glutamate, substance P, and calcitonin gene-related peptide. Indicated for neuropathic pain associated with diabetic peripheral neuropathy, post-herpetic neuralgia, fibromyalgia, generalized anxiety disorder (GAD), and adjunctive therapy for partial-onset seizures.

Pregabalin is an analogue of gamma-aminobutyric acid (GABA) that acts as a potent ligand at the alpha-2-delta auxiliary subunit of presynaptic voltage-gated calcium channels in the central nervous system. By reducing calcium influx into hyper-excited neurons, it curbs the pathological release of glutamate, substance P, and calcitonin gene-related peptide. Indicated for neuropathic pain associated with diabetic peripheral neuropathy, post-herpetic neuralgia, fibromyalgia, generalized anxiety disorder (GAD), and adjunctive therapy for partial-onset seizures.

Disulfiram is an alcohol-deterrent agent that acts by irreversibly inhibiting the hepatic enzyme aldehyde dehydrogenase (ALDH). Ingestion of alcohol during therapy causes a 5- to 10-fold accumulation of toxic acetaldehyde in the blood, precipitating an immediate, intensely unpleasant disulfiram-alcohol reaction (flushing, throbbing headache, palpitations, dyspnea, nausea, vomiting, hypotension). Indicated as an adjunct in the comprehensive management of chronic alcoholism to support enforced abstinence.

Flupentixol is a thioxanthene typical antipsychotic. At low doses (1-3 mg/day), it blocks presynaptic dopamine autoreceptors, stimulating dopamine turnover and exerting disinhibiting, mood-elevating, and anxiolytic effects; at higher doses, it blocks postsynaptic D2 receptors to control hallucinations and delusions. Indicated for maintenance treatment of schizophrenia, paranoid psychoses, and low-dose management of chronic depression with apathy.

Clonazepam and Escitalopram is a premier neuropsychiatric fixed-dose combination. Escitalopram, a high-affinity SSRI, selectively inhibits presynaptic serotonin reuptake to treat core depression and panic circuitry over time, while clonazepam, a long-acting benzodiazepine, delivers immediate allosteric enhancement of GABAA receptors, dampening initial SSRI-induced jitteriness, insomnia, and acute anxiety. Indicated for major depressive disorder with comorbid anxiety, panic disorder, and generalized anxiety disorder.

Nortriptyline Hydrochloride is a secondary amine tricyclic antidepressant and the active demethylated metabolite of amitriptyline. It selectively inhibits the reuptake of norepinephrine over serotonin, offering effective antidepressant and neuropathic analgesia with significantly less sedation, anticholinergic burden, and orthostatic hypotension than amitriptyline. Indicated for major depressive disorder and chronic neuropathic pain syndromes.

Etizolam is a thienodiazepine derivative structurally related to benzodiazepines. It acts as a potent full agonist at the GABAA receptor, producing significant anxiolytic, sedative-hypnotic, anticonvulsant, and muscle-relaxant actions with 6- to 10-fold higher potency than diazepam. Indicated for short-term management of generalized anxiety disorder, panic disorder, and insomnia associated with anxiety.

Alprazolam and Fluoxetine combines a fast-acting triazolobenzodiazepine with a selective serotonin reuptake inhibitor (SSRI). Alprazolam rapidly relieves acute psychic anxiety, insomnia, and agitation within hours, while fluoxetine provides sustained long-term modulation of central serotonergic pathways to treat underlying depressive and panic pathology over weeks. Indicated for major depressive disorder with comorbid anxiety or agitation.

Amisulpride is a substituted benzamide atypical antipsychotic. It acts with high selectivity as an antagonist at presynaptic and postsynaptic dopamine D2 and D3 receptors in the limbic system, with zero affinity for 5-HT, adrenergic, cholinergic, or histaminergic receptors. At low doses (50-300 mg), it preferentially blocks presynaptic autoreceptors, facilitating dopamine release and improving negative and cognitive symptoms; at higher doses (400-800 mg), it blocks postsynaptic D2 receptors to control positive psychotic symptoms. Indicated for schizophrenia with acute psychotic episodes and predominant negative symptoms.

Amitriptyline Hydrochloride is a prototype dibenzocycloheptadiene tricyclic antidepressant (TCA) on the WHO Model List of Essential Medicines. It inhibits the presynaptic neuronal reuptake of norepinephrine and serotonin, while also antagonizing muscarinic, histaminergic H1, and alpha-1 adrenergic receptors, and blocking neuronal sodium channels. Indicated for major depressive disorder, neuropathic pain (diabetic neuropathy, post-herpetic neuralgia), chronic tension-type headache and migraine prophylaxis, and nocturnal enuresis in children.

Amitriptyline Hydrochloride is a prototype dibenzocycloheptadiene tricyclic antidepressant (TCA) on the WHO Model List of Essential Medicines. It inhibits the presynaptic neuronal reuptake of norepinephrine and serotonin, while also antagonizing muscarinic, histaminergic H1, and alpha-1 adrenergic receptors, and blocking neuronal sodium channels. Indicated for major depressive disorder, neuropathic pain (diabetic neuropathy, post-herpetic neuralgia), chronic tension-type headache and migraine prophylaxis, and nocturnal enuresis in children.

Atracurium Besylate is an intermediate-acting non-depolarizing neuromuscular blocking agent on the WHO Model List of Essential Medicines. It competitively antagonizes nicotinic acetylcholine receptors at the motor endplate of skeletal muscles. It undergoes unique spontaneous non-enzymatic degradation at physiological pH and temperature (Hofmann elimination) and ester hydrolysis, making its duration of action independent of hepatic or renal function. Indicated as an adjunct to general anesthesia to facilitate endotracheal intubation and skeletal muscle relaxation during surgery or mechanical ventilation in intensive care.

Bromocriptine Mesylate is a semisynthetic ergot alkaloid derivative that acts as a potent dopamine D2 receptor agonist and partial D1 receptor antagonist. In the tuberoinfundibular pathway, it inhibits pituitary prolactin secretion; in the striatum, it stimulates dopamine receptors to improve motor deficits. Indicated for hyperprolactinemia-associated disorders (amenorrhea, galactorrhea, prolactin-secreting adenomas), acromegaly, and Parkinson's disease.

Chlordiazepoxide and Trifluoperazine combines an anxiolytic benzodiazepine with a high-potency phenothiazine antipsychotic. Trifluoperazine blocks postsynaptic dopamine D2 receptors in the mesolimbic pathway, subduing agitation and delusional thinking, while chlordiazepoxide modulates GABAA receptors to control anxiety and somatic tension. Indicated for anxiety states complicated by somatic obsessions, severe agitation, or mild psychotic symptoms.

Citicoline (Cytidine 5'-diphosphocholine / CDP-Choline) is a physiological intermediate in the biosynthesis of phosphatidylcholine, the major phospholipid component of neuronal membranes. It repairs damaged neuronal membranes, accelerates reabsorption of cerebral edema, inhibits free fatty acid release, and promotes acetylcholine and dopamine synthesis in the brain. Indicated for acute and subacute ischemic stroke recovery, traumatic brain injury (TBI), cognitive impairment, and vascular dementia.

Clonazepam is a long-acting benzodiazepine with potent anticonvulsant, muscle-relaxant, and anxiolytic actions on the WHO Model List of Essential Medicines. It allosterically modulates GABAA receptors, increasing frequency of chloride channel opening and dampening epileptic foci in the cortex and limbic system. Indicated for panic disorder with or without agoraphobia, Lennox-Gastaut syndrome, myoclonic and akinetic seizures, and absence seizures refractory to succinimides.

Diazepam is a prototype long-acting 1,4-benzodiazepine on the WHO Model List of Essential Medicines. It binds to the GABAA receptor complex in the limbic system, thalamus, and hypothalamus, facilitating GABA-mediated inhibitory neurotransmission. Possesses an active desmethyldiazepam metabolite with a prolonged elimination half-life (up to 100 hours). Indicated for management of anxiety disorders, acute alcohol withdrawal syndrome (delirium tremens), skeletal muscle spasm, and status epilepticus.

Donepezil Hydrochloride is a reversible, non-competitive, highly selective piperidine acetylcholinesterase (AChE) inhibitor on the WHO Model List of Essential Medicines. It increases synaptic acetylcholine availability in the cerebral cortex and hippocampus by inhibiting its breakdown. Indicated for mild, moderate, and severe dementia of the Alzheimer's type.

Gabapentin is a structural GABA analogue that acts selectively by binding to the alpha-2-delta-1 subunit of presynaptic voltage-dependent calcium channels, attenuating calcium influx in hyper-excited spinal and cerebral neurons. Indicated for post-herpetic neuralgia, painful diabetic peripheral neuropathy, and adjunctive therapy in partial-onset seizures with or without secondary generalization.

Gabapentin is a structural GABA analogue that acts selectively by binding to the alpha-2-delta-1 subunit of presynaptic voltage-dependent calcium channels, attenuating calcium influx in hyper-excited spinal and cerebral neurons. Indicated for post-herpetic neuralgia, painful diabetic peripheral neuropathy, and adjunctive therapy in partial-onset seizures with or without secondary generalization.

Imipramine Hydrochloride is a dibenzazepine derivative tricyclic antidepressant on the WHO Model List of Essential Medicines. It blocks the presynaptic reuptake of norepinephrine and serotonin. It is metabolized into desipramine, an active selective norepinephrine reuptake inhibitor. Indicated for major depressive disorder, panic disorder, and nocturnal enuresis in pediatric patients aged 6 years and older.

Lamotrigine is a phenyltriazine antiepileptic and mood stabilizer on the WHO Model List of Essential Medicines. It use- and voltage-dependently blocks voltage-gated sodium channels, suppressing the sustained repetitive firing of neurons and inhibiting the pathological release of the excitatory neurotransmitter glutamate. Indicated for focal seizures, generalized tonic-clonic seizures, Lennox-Gastaut syndrome, and maintenance treatment of bipolar I disorder to delay mood episodes.

Lignocaine (Lidocaine) Hydrochloride Gel 2% w/v is an evidence-based dermatological formulation. It acts by delivering targeted active therapeutic ingredients to cutaneous lesions to relieve skin pathology, restore barrier integrity, and manage dermatoses.

Lithium Carbonate is the classical mood-stabilizing monovalent cation on the WHO Model List of Essential Medicines. It alters neuronal sodium transport, inhibits inositol monophosphatase (depleting free intracellular inositol and dampening phosphoinositide signaling), and inhibits glycogen synthase kinase-3 beta (GSK-3beta), providing neuroprotective neuroplasticity. Indicated for the treatment of acute manic and mixed episodes in bipolar disorder and long-term maintenance therapy to prevent bipolar relapses and decrease suicide risk.

Lorazepam is a high-potency, intermediate-acting 3-hydroxy benzodiazepine on the WHO Model List of Essential Medicines. It enhances GABA-mediated synaptic inhibition by binding to GABAA receptors. Because it undergoes direct hepatic glucuronidation to inactive metabolites without intermediate oxidative CYP450 steps, it is the benzodiazepine of choice in patients with hepatic impairment and the elderly. Indicated for short-term management of severe anxiety, insomnia associated with anxiety, acute status epilepticus, and pre-anesthetic sedation.

Lorazepam is a high-potency, intermediate-acting 3-hydroxy benzodiazepine on the WHO Model List of Essential Medicines. It enhances GABA-mediated synaptic inhibition by binding to GABAA receptors. Because it undergoes direct hepatic glucuronidation to inactive metabolites without intermediate oxidative CYP450 steps, it is the benzodiazepine of choice in patients with hepatic impairment and the elderly. Indicated for short-term management of severe anxiety, insomnia associated with anxiety, acute status epilepticus, and pre-anesthetic sedation.

Memantine Hydrochloride is an uncompetitive, low-to-moderate affinity, voltage-dependent N-methyl-D-aspartate (NMDA) receptor antagonist. Pathological chronic exposure to high glutamate concentrations produces excitotoxic neuronal death in Alzheimer's disease; memantine blocks pathological tonic glutamate influx through NMDA channels while preserving physiological phasic neurotransmission necessary for learning and memory. Indicated for moderate-to-severe dementia of the Alzheimer's type.

Mirtazapine is a noradrenergic and specific serotonergic antidepressant (NaSSA). It antagonizes presynaptic alpha-2 auto- and hetero-receptors, boosting central release of both norepinephrine and serotonin. It selectively blocks postsynaptic 5-HT2 and 5-HT3 receptors (sparing patients from SSRI-associated nausea, anxiety, and sexual dysfunction) while enhancing 5-HT1A-mediated transmission. It is also a potent H1 antagonist. Indicated for major depressive disorder, particularly in patients with severe insomnia, anxiety, and weight loss.

Nitrazepam is an intermediate-to-long-acting nitrobenzodiazepine hypnotic agent. It binds to the GABAA receptor complex, increasing chloride conductance, hyperpolarizing neuronal membranes, and suppressing the brainstem reticular activating system, shortening sleep latency and reducing nocturnal awakenings. Indicated for short-term severe, disabling insomnia and infantile spasms (West syndrome).

Olanzapine is a second-generation atypical thienobenzodiazepine antipsychotic and mood stabilizer on the WHO Model List of Essential Medicines. It acts by antagonizing serotonin 5-HT2A and dopamine D2 receptors, with high affinity for 5-HT2C, H1, and alpha-1 receptors, delivering potent antipsychotic efficacy with low extrapyramidal liability. Indicated for schizophrenia, acute manic or mixed episodes in bipolar I disorder, maintenance in bipolar disorder, and treatment-resistant depression (in combination with fluoxetine).

Olanzapine is a second-generation atypical thienobenzodiazepine antipsychotic and mood stabilizer on the WHO Model List of Essential Medicines. It acts by antagonizing serotonin 5-HT2A and dopamine D2 receptors, with high affinity for 5-HT2C, H1, and alpha-1 receptors, delivering potent antipsychotic efficacy with low extrapyramidal liability. Indicated for schizophrenia, acute manic or mixed episodes in bipolar I disorder, maintenance in bipolar disorder, and treatment-resistant depression (in combination with fluoxetine).

Paroxetine is a phenylpiperidine-derivative selective serotonin reuptake inhibitor (SSRI) with the highest affinity for SERT among all SSRIs. It also exhibits mild anticholinergic and nitric oxide synthase-inhibiting properties. Prolonged-release formulation ensures gradual drug release over 24 hours, mitigating peak-related gastrointestinal and sedative adverse effects. Indicated for major depressive disorder, panic disorder, social anxiety disorder, generalized anxiety disorder, and PTSD.

Phenobarbitone (Phenobarbital) is a long-acting barbiturate anticonvulsant on the WHO Model List of Essential Medicines. It binds allosterically to GABAA receptors, prolonging the open duration of neuronal chloride ion channels, enhancing GABA-mediated inhibition, and suppressing glutamate-mediated excitation. Indicated for generalized tonic-clonic seizures, focal seizures, and neonatal seizures.

Piracetam is the prototypical racetam nootropic agent. It binds to neuronal membranes to restore membrane fluidity, allosterically potentiates AMPA-type glutamate receptors, and improves cerebral microcirculation by reducing platelet aggregation and erythrocyte adhesion to vascular endothelium. Indicated for cortical myoclonus (as adjunctive therapy), cognitive disorders, post-stroke rehabilitation, and vertigo.

Piracetam is the prototypical racetam nootropic agent. It binds to neuronal membranes to restore membrane fluidity, allosterically potentiates AMPA-type glutamate receptors, and improves cerebral microcirculation by reducing platelet aggregation and erythrocyte adhesion to vascular endothelium. Indicated for cortical myoclonus (as adjunctive therapy), cognitive disorders, post-stroke rehabilitation, and vertigo.

Quetiapine Fumarate is a dibenzothiazepine atypical antipsychotic. It exhibits antagonist activity at serotonin 5-HT2A and dopamine D2 receptors, with rapid dissociation from D2 receptors ("hit-and-run" kinetics) which minimizes extrapyramidal symptoms and hyperprolactinemia. Its active metabolite, norquetiapine, potently inhibits norepinephrine reuptake (NET) and acts as a 5-HT1A partial agonist, conferring distinctive antidepressant efficacy. Indicated for schizophrenia, acute manic episodes in bipolar I disorder, bipolar depression, and adjunctive therapy in major depressive disorder.

Quetiapine Fumarate is a dibenzothiazepine atypical antipsychotic. It exhibits antagonist activity at serotonin 5-HT2A and dopamine D2 receptors, with rapid dissociation from D2 receptors ("hit-and-run" kinetics) which minimizes extrapyramidal symptoms and hyperprolactinemia. Its active metabolite, norquetiapine, potently inhibits norepinephrine reuptake (NET) and acts as a 5-HT1A partial agonist, conferring distinctive antidepressant efficacy. Indicated for schizophrenia, acute manic episodes in bipolar I disorder, bipolar depression, and adjunctive therapy in major depressive disorder.

Risperidone and Trihexyphenidyl (Benzhexol) is a therapeutic combination designed to provide antipsychotic efficacy while preventing drug-induced movement disorders. Risperidone, a benzisoxazole atypical antipsychotic, blocks dopamine D2 and serotonin 5-HT2A receptors to control psychosis, while trihexyphenidyl, a centrally acting anticholinergic agent, blocks muscarinic M1 receptors to restore the dopamine-acetylcholine balance in the basal ganglia, preventing extrapyramidal symptoms (acute dystonia, parkinsonian rigidity, tremors, akathisia). Indicated for schizophrenia, schizoaffective disorder, and severe psychotic agitation complicated by high extrapyramidal risk.

Risperidone is a benzisoxazole second-generation atypical antipsychotic on the WHO Model List of Essential Medicines. It possesses high-affinity antagonism at serotonin 5-HT2A and dopamine D2 receptors, as well as alpha-1 and alpha-2 adrenergic and H1 receptors. Indicated for schizophrenia in adults and adolescents, acute mania in bipolar I disorder, and irritability/severe aggression associated with autistic disorder in children.

Sertraline Hydrochloride is a selective serotonin reuptake inhibitor (SSRI) on the WHO Model List of Essential Medicines. It selectively inhibits the membrane transporter SERT, increasing synaptic serotonin concentrations. Also exhibits weak dopamine reuptake inhibition (DAT), which may assist with fatigue and cognitive slowing. Favored in cardiac patients due to low arrhythmogenic risk. Indicated for major depressive disorder, panic disorder, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), and social anxiety disorder.

Sertraline Hydrochloride is a selective serotonin reuptake inhibitor (SSRI) on the WHO Model List of Essential Medicines. It selectively inhibits the membrane transporter SERT, increasing synaptic serotonin concentrations. Also exhibits weak dopamine reuptake inhibition (DAT), which may assist with fatigue and cognitive slowing. Favored in cardiac patients due to low arrhythmogenic risk. Indicated for major depressive disorder, panic disorder, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), and social anxiety disorder.

Sertraline Hydrochloride is a selective serotonin reuptake inhibitor (SSRI) on the WHO Model List of Essential Medicines. It selectively inhibits the membrane transporter SERT, increasing synaptic serotonin concentrations. Also exhibits weak dopamine reuptake inhibition (DAT), which may assist with fatigue and cognitive slowing. Favored in cardiac patients due to low arrhythmogenic risk. Indicated for major depressive disorder, panic disorder, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), and social anxiety disorder.

Sodium Valproate / Divalproex Sodium is a broad-spectrum antiepileptic and mood stabilizer on the WHO Model List of Essential Medicines. It increases brain gamma-aminobutyric acid (GABA) levels by inhibiting GABA transaminase and succinic semialdehyde dehydrogenase, while blocking voltage-gated T-type calcium channels and sustained repetitive firing of voltage-sensitive sodium channels. Indicated for generalized and focal epilepsy (absence, myoclonic, tonic-clonic seizures), acute manic episodes in bipolar disorder, and migraine prophylaxis.

Sodium Valproate / Divalproex Sodium is a broad-spectrum antiepileptic and mood stabilizer on the WHO Model List of Essential Medicines. It increases brain gamma-aminobutyric acid (GABA) levels by inhibiting GABA transaminase and succinic semialdehyde dehydrogenase, while blocking voltage-gated T-type calcium channels and sustained repetitive firing of voltage-sensitive sodium channels. Indicated for generalized and focal epilepsy (absence, myoclonic, tonic-clonic seizures), acute manic episodes in bipolar disorder, and migraine prophylaxis.

Trihexyphenidyl Hydrochloride (Benzhexol) is a synthetic tertiary amine centrally acting anticholinergic (antimuscarinic) agent on the WHO Model List of Essential Medicines. It competitively antagonizes muscarinic acetylcholine receptors (M1) in the corpus striatum, restoring balance between dopamine deficiency and cholinergic excess. Indicated for adjunctive treatment of Parkinson's disease (particularly for reducing resting tremor and rigidity) and prevention/treatment of drug-induced extrapyramidal symptoms (acute dystonia, akathisia, parkinsonism) caused by neuroleptics.

Vecuronium Bromide is an intermediate-acting monoquaternary aminosteroid non-depolarizing neuromuscular blocking agent on the WHO Model List of Essential Medicines. It competitively blocks acetylcholine at motor endplate nicotinic receptors. Unlike atracurium or tubocurarine, it does not induce histamine release or autonomic ganglion blockade, conferring exceptional cardiovascular stability without tachycardia or hypotension. Indicated for skeletal muscle relaxation during surgical procedures and mechanical ventilation.

Zolpidem Tartrate is an imidazopyridine non-benzodiazepine hypnotic agent. It binds selectively with high affinity to the alpha-1 subunit-containing GABAA receptor subtype (omega-1 receptor) in the brain, sparing alpha-2 and alpha-3 subunits, resulting in potent sleep-inducing action with minimal myorelaxant and anticonvulsant effects. Indicated for short-term treatment of insomnia characterized by difficulties with sleep initiation.

Clobazam is a 1,5-benzodiazepine with preferential affinity for the alpha-2 subunit of GABAA receptors over alpha-1, conferring potent anticonvulsant and anxiolytic efficacy with reduced sedative and motor impairment compared to traditional 1,4-benzodiazepines. Its active metabolite, N-desmethylclobazam, provides prolonged neuronal stabilization. Indicated as adjunctive therapy for refractory epilepsy, Lennox-Gastaut syndrome, and severe anxiety.

Gabapentin and Nortriptyline is a dual-acting neuropathic pain formulation combining a gabapentinoid with a tricyclic antidepressant. Gabapentin decreases excitatory neurotransmitter exocytosis by binding to alpha-2-delta subunits of voltage-gated calcium channels, while nortriptyline blocks presynaptic reuptake of noradrenaline and serotonin, reinforcing endogenous descending spinal analgesia. Indicated for diabetic peripheral neuropathy, post-herpetic neuralgia, and chronic radiculopathy.

Cinnarizine is a piperazine-derivative labyrinthine sedative and peripheral vasodilator. It selectively blocks voltage-gated T-type calcium channels, inhibiting trans-membrane calcium influx in vestibular sensory cells and vascular smooth muscle, improving labyrinthine microcirculation and suppressing motion-induced vestibular overstimulation. Indicated for vestibular vertigo, motion sickness prophylaxis, and peripheral vascular disorders.

Clomipramine Hydrochloride is a chlorinated tricyclic antidepressant with exceptionally potent and selective serotonin reuptake inhibition compared to other TCAs. Its demethylated metabolite acts as a norepinephrine reuptake inhibitor. Considered the gold-standard pharmacological agent for severe obsessive-compulsive disorder (OCD). Also indicated for treatment-resistant depression, panic disorder, and cataplexy associated with narcolepsy.

Fluvoxamine Maleate is a selective serotonin reuptake inhibitor (SSRI) with notable affinity for sigma-1 receptors in the central nervous system, contributing to neuroprotective and anti-inflammatory effects. Indicated primarily for obsessive-compulsive disorder (OCD) and social anxiety disorder.

Aripiprazole is a third-generation quinolinone atypical antipsychotic functioning as a dopamine-serotonin system stabilizer. It acts as a partial agonist at dopamine D2 and D3 receptors and serotonin 5-HT1A receptors, and an antagonist at 5-HT2A receptors. By acting as a partial agonist, it buffers hyperactive dopamine in mesolimbic circuits (alleviating positive symptoms) while supporting dopamine activity in mesocortical circuits (improving negative symptoms and avoiding parkinsonism and hyperprolactinemia). Indicated for schizophrenia, acute manic/mixed bipolar episodes, adjunctive treatment in major depression, and Tourette's disorder.

Carbamazepine is an iminostilbene dibenzazepine antiepileptic on the WHO Model List of Essential Medicines. It voltage- and use-dependently blocks neuronal voltage-gated sodium channels, preventing repetitive neuronal firing and inhibiting spread of seizure discharges. It is the gold-standard first-line agent for trigeminal neuralgia. Indicated for focal (partial) seizures, generalized tonic-clonic seizures, trigeminal neuralgia, and acute mania/bipolar maintenance.

Chlordiazepoxide is the historical first-discovered benzodiazepine. It acts by binding to stereospecific GABAA receptors in the central nervous system, enhancing chloride ion channel opening and augmenting GABA-mediated neuronal inhibition. Possesses active metabolites with a long elimination half-life. Indicated for short-term relief of severe anxiety disorders and acute management of alcohol withdrawal symptoms.

Donepezil Hydrochloride is a reversible, non-competitive, highly selective piperidine acetylcholinesterase (AChE) inhibitor on the WHO Model List of Essential Medicines. It increases synaptic acetylcholine availability in the cerebral cortex and hippocampus by inhibiting its breakdown. Indicated for mild, moderate, and severe dementia of the Alzheimer's type.

Duloxetine is a potent, balanced dual serotonin and norepinephrine reuptake inhibitor (SNRI). It inhibits both 5-HT and NE reuptake in the central nervous system, boosting descending inhibitory pain pathways and elevating mood. Gastro-resistant formulation protects the acid-labile drug from gastric degradation. Indicated for major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain.

Clonazepam and Escitalopram is a premier neuropsychiatric fixed-dose combination. Escitalopram, a high-affinity SSRI, selectively inhibits presynaptic serotonin reuptake to treat core depression and panic circuitry over time, while clonazepam, a long-acting benzodiazepine, delivers immediate allosteric enhancement of GABAA receptors, dampening initial SSRI-induced jitteriness, insomnia, and acute anxiety. Indicated for major depressive disorder with comorbid anxiety, panic disorder, and generalized anxiety disorder.

Gabapentin is a structural GABA analogue that acts selectively by binding to the alpha-2-delta-1 subunit of presynaptic voltage-dependent calcium channels, attenuating calcium influx in hyper-excited spinal and cerebral neurons. Indicated for post-herpetic neuralgia, painful diabetic peripheral neuropathy, and adjunctive therapy in partial-onset seizures with or without secondary generalization.

Mirtazapine is a noradrenergic and specific serotonergic antidepressant (NaSSA). It antagonizes presynaptic alpha-2 auto- and hetero-receptors, boosting central release of both norepinephrine and serotonin. It selectively blocks postsynaptic 5-HT2 and 5-HT3 receptors (sparing patients from SSRI-associated nausea, anxiety, and sexual dysfunction) while enhancing 5-HT1A-mediated transmission. It is also a potent H1 antagonist. Indicated for major depressive disorder, particularly in patients with severe insomnia, anxiety, and weight loss.

Modafinil is an atypical wakefulness-promoting agent. Unlike classical amphetamines, it acts as a selective, low-affinity dopamine transporter (DAT) inhibitor while stimulating hypocretin/orexin, histamine, and alpha-1 adrenergic systems in the hypothalamus and tuberomammillary nucleus, promoting alertness without peripheral sympathomimetic overstimulation or rebound hypersomnolence. Indicated for excessive daytime sleepiness associated with narcolepsy, obstructive sleep apnea (OSA), and shift work sleep disorder (SWSD).

Phenobarbitone (Phenobarbital) is a long-acting barbiturate anticonvulsant on the WHO Model List of Essential Medicines. It binds allosterically to GABAA receptors, prolonging the open duration of neuronal chloride ion channels, enhancing GABA-mediated inhibition, and suppressing glutamate-mediated excitation. Indicated for generalized tonic-clonic seizures, focal seizures, and neonatal seizures.

Pregabalin and Nortriptyline combines a gabapentinoid voltage-gated calcium channel modulator with a tricyclic antidepressant (TCA). Pregabalin binds the alpha-2-delta auxiliary subunit of presynaptic voltage-gated calcium channels in the CNS, diminishing calcium influx and the exocytosis of excitatory neurotransmitters (glutamate, substance P, noradrenaline). Nortriptyline inhibits presynaptic reuptake of serotonin and noradrenaline, enhancing descending inhibitory pain pathways in the spinal dorsal horn. Indicated for moderate-to-severe neuropathic pain, diabetic peripheral neuropathy, and post-herpetic neuralgia.

Quetiapine Fumarate is a dibenzothiazepine atypical antipsychotic. It exhibits antagonist activity at serotonin 5-HT2A and dopamine D2 receptors, with rapid dissociation from D2 receptors ("hit-and-run" kinetics) which minimizes extrapyramidal symptoms and hyperprolactinemia. Its active metabolite, norquetiapine, potently inhibits norepinephrine reuptake (NET) and acts as a 5-HT1A partial agonist, conferring distinctive antidepressant efficacy. Indicated for schizophrenia, acute manic episodes in bipolar I disorder, bipolar depression, and adjunctive therapy in major depressive disorder.

Nicotine Polacrilex (Chewing Gum / Orally Disintegrating Strips) is a form of Nicotine Replacement Therapy (NRT) on the WHO Model List of Essential Medicines. It delivers controlled, low doses of medicinal nicotine systemically across the buccal mucosa without the carcinogenic tars, carbon monoxide, or combustion toxins of tobacco smoke, binding to nicotinic acetylcholine receptors in the brain to relieve withdrawal symptoms and craving. Indicated as an aid in smoking cessation and tobacco harm reduction.

Lamotrigine is a phenyltriazine antiepileptic and mood stabilizer on the WHO Model List of Essential Medicines. It use- and voltage-dependently blocks voltage-gated sodium channels, suppressing the sustained repetitive firing of neurons and inhibiting the pathological release of the excitatory neurotransmitter glutamate. Indicated for focal seizures, generalized tonic-clonic seizures, Lennox-Gastaut syndrome, and maintenance treatment of bipolar I disorder to delay mood episodes.

Levetiracetam is a pyrrolidone derivative second-generation antiepileptic on the WHO Model List of Essential Medicines. It exhibits a unique mechanism of action, binding stereoselectively to synaptic vesicle protein 2A (SV2A) in presynaptic terminals, modulating exocytosis and restraining pathological vesicle release of excitatory neurotransmitters without affecting normal neurotransmission. Demonstrates near 100% oral bioavailability and minimal hepatic CYP450 metabolism. Indicated as monotherapy and adjunctive therapy for focal seizures, myoclonic seizures in juvenile myoclonic epilepsy, and primary generalized tonic-clonic seizures.

Amantadine Hydrochloride is a synthetic tricyclic amine that acts as a low-affinity, uncompetitive antagonist at NMDA glutamate receptors, while stimulating presynaptic dopamine release and inhibiting dopamine reuptake in the striatum. Indicated for the treatment of levodopa-induced dyskinesias in Parkinson's disease, idiopathic Parkinson's symptoms, and drug-induced extrapyramidal reactions.

Betahistine is a synthetic structural histamine analogue that acts as a strong antagonist at histamine H3 receptors and a weak agonist at histamine H1 receptors. By blocking H3 autoreceptors in the inner ear and vestibular nuclei, it enhances local histamine release, dilating precapillary sphincters in the stria vascularis and microvasculature of the labyrinth, thereby reducing endolymphatic hydrops pressure. Indicated for Meniere's disease (characterized by the triad of vertigo, tinnitus, and sensorineural hearing loss) and symptomatic vestibular vertigo.

Betahistine is a synthetic structural histamine analogue that acts as a strong antagonist at histamine H3 receptors and a weak agonist at histamine H1 receptors. By blocking H3 autoreceptors in the inner ear and vestibular nuclei, it enhances local histamine release, dilating precapillary sphincters in the stria vascularis and microvasculature of the labyrinth, thereby reducing endolymphatic hydrops pressure. Indicated for Meniere's disease (characterized by the triad of vertigo, tinnitus, and sensorineural hearing loss) and symptomatic vestibular vertigo.

Cerebroprotein Hydrolysate is a purified porcine brain-derived peptide preparation containing neurotrophic factors and low-molecular-weight neuropeptides. It mimics the actions of endogenous neurotrophic factors (such as NGF and BDNF), crossing the blood-brain barrier to promote neuronal survival, stimulate neurite outgrowth, improve synaptic plasticity, and protect neurons against excitotoxicity and ischemic hypoxia. Indicated for acute ischemic stroke, traumatic brain injury, and vascular dementia.

Chlordiazepoxide and Amitriptyline is a classic psychotropic formulation combining a benzodiazepine with a tricyclic antidepressant (TCA). Chlordiazepoxide provides prompt reduction of psychic tension, anxiety, and agitation via GABAA receptor enhancement, while amitriptyline inhibits the neuronal reuptake of norepinephrine and serotonin to resolve underlying depressive illness. Indicated for moderate-to-severe depression associated with prominent anxiety, agitation, and insomnia.

Cinnarizine is a piperazine-derivative labyrinthine sedative and peripheral vasodilator. It selectively blocks voltage-gated T-type calcium channels, inhibiting trans-membrane calcium influx in vestibular sensory cells and vascular smooth muscle, improving labyrinthine microcirculation and suppressing motion-induced vestibular overstimulation. Indicated for vestibular vertigo, motion sickness prophylaxis, and peripheral vascular disorders.

Citicoline and Piracetam is a synergistic neuroprotective and nootropic formulation. Citicoline serves as an essential intermediate in the biosynthesis of structural neuronal membrane phosphatidylcholine and raises brain acetylcholine and dopamine levels, while piracetam, a cyclic GABA derivative, allosterically modulates AMPA receptors, improves erythrocyte deformability, enhances microvascular cerebral blood flow, and elevates neuronal ATP turnover. Indicated for cognitive dysfunction, acute ischemic stroke recovery, vascular dementia, post-concussion syndrome, and senile memory impairment.

Clobazam is a 1,5-benzodiazepine with preferential affinity for the alpha-2 subunit of GABAA receptors over alpha-1, conferring potent anticonvulsant and anxiolytic efficacy with reduced sedative and motor impairment compared to traditional 1,4-benzodiazepines. Its active metabolite, N-desmethylclobazam, provides prolonged neuronal stabilization. Indicated as adjunctive therapy for refractory epilepsy, Lennox-Gastaut syndrome, and severe anxiety.

Sodium Valproate / Divalproex Sodium is a broad-spectrum antiepileptic and mood stabilizer on the WHO Model List of Essential Medicines. It increases brain gamma-aminobutyric acid (GABA) levels by inhibiting GABA transaminase and succinic semialdehyde dehydrogenase, while blocking voltage-gated T-type calcium channels and sustained repetitive firing of voltage-sensitive sodium channels. Indicated for generalized and focal epilepsy (absence, myoclonic, tonic-clonic seizures), acute manic episodes in bipolar disorder, and migraine prophylaxis.

Dosulepin (Dothiepin) Hydrochloride is a thio-derivative tricyclic antidepressant. It blocks the reuptake of norepinephrine and serotonin while exerting significant central sedative and anxiolytic actions via H1 and 5-HT2 antagonism. Indicated for major depressive illness, particularly when associated with prominent anxiety, agitation, and sleep disturbance.

Dosulepin (Dothiepin) Hydrochloride is a thio-derivative tricyclic antidepressant. It blocks the reuptake of norepinephrine and serotonin while exerting significant central sedative and anxiolytic actions via H1 and 5-HT2 antagonism. Indicated for major depressive illness, particularly when associated with prominent anxiety, agitation, and sleep disturbance.

Flupentixol and Melitracen is a classic psychoanaleptic fixed-dose combination. Flupentixol, a thioxanthene derivative, acts at low doses (0.5 mg) preferentially on presynaptic dopamine autoreceptors to increase dopaminergic tone and relieve apathy and anxiety, while melitracen, a bipolar tricyclic antidepressant, inhibits norepinephrine and serotonin reuptake. Together, they provide activating, anxiolytic, and mood-lifting action without causing marked sedation. Indicated for psychogenic depression, depressive neuroses, masked depression, and psychosomatic disorders accompanied by anxiety and apathy.

Gabapentin is a structural GABA analogue that acts selectively by binding to the alpha-2-delta-1 subunit of presynaptic voltage-dependent calcium channels, attenuating calcium influx in hyper-excited spinal and cerebral neurons. Indicated for post-herpetic neuralgia, painful diabetic peripheral neuropathy, and adjunctive therapy in partial-onset seizures with or without secondary generalization.

Gabapentin is a structural GABA analogue that acts selectively by binding to the alpha-2-delta-1 subunit of presynaptic voltage-dependent calcium channels, attenuating calcium influx in hyper-excited spinal and cerebral neurons. Indicated for post-herpetic neuralgia, painful diabetic peripheral neuropathy, and adjunctive therapy in partial-onset seizures with or without secondary generalization.

Levetiracetam is a pyrrolidone derivative second-generation antiepileptic on the WHO Model List of Essential Medicines. It exhibits a unique mechanism of action, binding stereoselectively to synaptic vesicle protein 2A (SV2A) in presynaptic terminals, modulating exocytosis and restraining pathological vesicle release of excitatory neurotransmitters without affecting normal neurotransmission. Demonstrates near 100% oral bioavailability and minimal hepatic CYP450 metabolism. Indicated as monotherapy and adjunctive therapy for focal seizures, myoclonic seizures in juvenile myoclonic epilepsy, and primary generalized tonic-clonic seizures.

Levetiracetam is a pyrrolidone derivative second-generation antiepileptic on the WHO Model List of Essential Medicines. It exhibits a unique mechanism of action, binding stereoselectively to synaptic vesicle protein 2A (SV2A) in presynaptic terminals, modulating exocytosis and restraining pathological vesicle release of excitatory neurotransmitters without affecting normal neurotransmission. Demonstrates near 100% oral bioavailability and minimal hepatic CYP450 metabolism. Indicated as monotherapy and adjunctive therapy for focal seizures, myoclonic seizures in juvenile myoclonic epilepsy, and primary generalized tonic-clonic seizures.

Levetiracetam is a pyrrolidone derivative second-generation antiepileptic on the WHO Model List of Essential Medicines. It exhibits a unique mechanism of action, binding stereoselectively to synaptic vesicle protein 2A (SV2A) in presynaptic terminals, modulating exocytosis and restraining pathological vesicle release of excitatory neurotransmitters without affecting normal neurotransmission. Demonstrates near 100% oral bioavailability and minimal hepatic CYP450 metabolism. Indicated as monotherapy and adjunctive therapy for focal seizures, myoclonic seizures in juvenile myoclonic epilepsy, and primary generalized tonic-clonic seizures.

Levodopa and Carbidopa is the gold-standard cornerstone treatment for Parkinson's disease on the WHO Model List of Essential Medicines. Levodopa crosses the blood-brain barrier via large neutral amino acid transporters and is decarboxylated by central DOPA decarboxylase into active dopamine in the striatum. Carbidopa does not penetrate the blood-brain barrier; it inhibits peripheral decarboxylation, preventing peripheral dopamine-mediated nausea and cardiovascular toxicity while increasing central levodopa availability tenfold. Indicated for Parkinson's disease and post-encephalitic parkinsonism.

Piracetam is the prototypical racetam nootropic agent. It binds to neuronal membranes to restore membrane fluidity, allosterically potentiates AMPA-type glutamate receptors, and improves cerebral microcirculation by reducing platelet aggregation and erythrocyte adhesion to vascular endothelium. Indicated for cortical myoclonus (as adjunctive therapy), cognitive disorders, post-stroke rehabilitation, and vertigo.

Pregabalin and Nortriptyline combines a gabapentinoid voltage-gated calcium channel modulator with a tricyclic antidepressant (TCA). Pregabalin binds the alpha-2-delta auxiliary subunit of presynaptic voltage-gated calcium channels in the CNS, diminishing calcium influx and the exocytosis of excitatory neurotransmitters (glutamate, substance P, noradrenaline). Nortriptyline inhibits presynaptic reuptake of serotonin and noradrenaline, enhancing descending inhibitory pain pathways in the spinal dorsal horn. Indicated for moderate-to-severe neuropathic pain, diabetic peripheral neuropathy, and post-herpetic neuralgia.

Pregabalin is an analogue of gamma-aminobutyric acid (GABA) that acts as a potent ligand at the alpha-2-delta auxiliary subunit of presynaptic voltage-gated calcium channels in the central nervous system. By reducing calcium influx into hyper-excited neurons, it curbs the pathological release of glutamate, substance P, and calcitonin gene-related peptide. Indicated for neuropathic pain associated with diabetic peripheral neuropathy, post-herpetic neuralgia, fibromyalgia, generalized anxiety disorder (GAD), and adjunctive therapy for partial-onset seizures.

Sodium Valproate / Divalproex Sodium is a broad-spectrum antiepileptic and mood stabilizer on the WHO Model List of Essential Medicines. It increases brain gamma-aminobutyric acid (GABA) levels by inhibiting GABA transaminase and succinic semialdehyde dehydrogenase, while blocking voltage-gated T-type calcium channels and sustained repetitive firing of voltage-sensitive sodium channels. Indicated for generalized and focal epilepsy (absence, myoclonic, tonic-clonic seizures), acute manic episodes in bipolar disorder, and migraine prophylaxis.

Sodium Valproate / Divalproex Sodium is a broad-spectrum antiepileptic and mood stabilizer on the WHO Model List of Essential Medicines. It increases brain gamma-aminobutyric acid (GABA) levels by inhibiting GABA transaminase and succinic semialdehyde dehydrogenase, while blocking voltage-gated T-type calcium channels and sustained repetitive firing of voltage-sensitive sodium channels. Indicated for generalized and focal epilepsy (absence, myoclonic, tonic-clonic seizures), acute manic episodes in bipolar disorder, and migraine prophylaxis.

Sodium Valproate / Divalproex Sodium is a broad-spectrum antiepileptic and mood stabilizer on the WHO Model List of Essential Medicines. It increases brain gamma-aminobutyric acid (GABA) levels by inhibiting GABA transaminase and succinic semialdehyde dehydrogenase, while blocking voltage-gated T-type calcium channels and sustained repetitive firing of voltage-sensitive sodium channels. Indicated for generalized and focal epilepsy (absence, myoclonic, tonic-clonic seizures), acute manic episodes in bipolar disorder, and migraine prophylaxis.

Tetrabenazine is a reversible, high-affinity inhibitor of vesicular monoamine transporter type 2 (VMAT2). By blocking VMAT2 in presynaptic nerve terminals, it inhibits the packaging and storage of monoamines (dopamine, serotonin, norepinephrine), leading to depletion of monoamine stores and reducing hyperkinetic involuntary movements. Indicated for the treatment of chorea associated with Huntington's disease and refractory tardive dyskinesia.

Epalrestat Sustained Release Tablets 150 mg is an evidence-based neuropsychiatric and central nervous system formulation. It acts by modulating neuronal neurotransmission, receptor kinetics, or ion channel conductance to manage neurological and mental health disorders.

Agomelatine is a novel melatonergic antidepressant. It acts as a potent agonist at melatonin MT1 and MT2 receptors and a selective antagonist at serotonin 5-HT2C receptors in the frontal cortex, resynchronizing circadian sleep-wake cycles and elevating local dopamine and norepinephrine levels without increasing serotonin. Indicated for the treatment of major depressive episodes in adults.

Alprazolam and Propranolol Hydrochloride is a synergistic psychotropic-cardiovascular formulation combining a triazolobenzodiazepine with a non-selective beta-adrenergic blocker. Alprazolam enhances central inhibitory GABAergic neurotransmission at the GABAA receptor, relieving psychological panic and tension, while propranolol competitively antagonizes peripheral beta-1 and beta-2 adrenergic receptors, curbing somatic autonomic manifestations of anxiety (palpitations, resting tachycardia, tremors, sweating). Indicated for situational anxiety, panic disorder with severe autonomic hyperactivity, and performance anxiety.

Alprazolam and Propranolol Hydrochloride is a synergistic psychotropic-cardiovascular formulation combining a triazolobenzodiazepine with a non-selective beta-adrenergic blocker. Alprazolam enhances central inhibitory GABAergic neurotransmission at the GABAA receptor, relieving psychological panic and tension, while propranolol competitively antagonizes peripheral beta-1 and beta-2 adrenergic receptors, curbing somatic autonomic manifestations of anxiety (palpitations, resting tachycardia, tremors, sweating). Indicated for situational anxiety, panic disorder with severe autonomic hyperactivity, and performance anxiety.

Alprazolam and Sertraline pairs an immediate-acting high-potency benzodiazepine with an SSRI. Alprazolam bridges the initial 2-4 week lag phase of antidepressant therapy by rapidly controlling severe anxiety, panicky distress, and insomnia, while sertraline elevates synaptic serotonin to alleviate core depressive illness. Indicated for major depressive episodes accompanied by prominent anxiety symptoms.

Alprazolam and Sertraline pairs an immediate-acting high-potency benzodiazepine with an SSRI. Alprazolam bridges the initial 2-4 week lag phase of antidepressant therapy by rapidly controlling severe anxiety, panicky distress, and insomnia, while sertraline elevates synaptic serotonin to alleviate core depressive illness. Indicated for major depressive episodes accompanied by prominent anxiety symptoms.

Amisulpride is a substituted benzamide atypical antipsychotic. It acts with high selectivity as an antagonist at presynaptic and postsynaptic dopamine D2 and D3 receptors in the limbic system, with zero affinity for 5-HT, adrenergic, cholinergic, or histaminergic receptors. At low doses (50-300 mg), it preferentially blocks presynaptic autoreceptors, facilitating dopamine release and improving negative and cognitive symptoms; at higher doses (400-800 mg), it blocks postsynaptic D2 receptors to control positive psychotic symptoms. Indicated for schizophrenia with acute psychotic episodes and predominant negative symptoms.

Amisulpride is a substituted benzamide atypical antipsychotic. It acts with high selectivity as an antagonist at presynaptic and postsynaptic dopamine D2 and D3 receptors in the limbic system, with zero affinity for 5-HT, adrenergic, cholinergic, or histaminergic receptors. At low doses (50-300 mg), it preferentially blocks presynaptic autoreceptors, facilitating dopamine release and improving negative and cognitive symptoms; at higher doses (400-800 mg), it blocks postsynaptic D2 receptors to control positive psychotic symptoms. Indicated for schizophrenia with acute psychotic episodes and predominant negative symptoms.

Amitriptyline Hydrochloride is a prototype dibenzocycloheptadiene tricyclic antidepressant (TCA) on the WHO Model List of Essential Medicines. It inhibits the presynaptic neuronal reuptake of norepinephrine and serotonin, while also antagonizing muscarinic, histaminergic H1, and alpha-1 adrenergic receptors, and blocking neuronal sodium channels. Indicated for major depressive disorder, neuropathic pain (diabetic neuropathy, post-herpetic neuralgia), chronic tension-type headache and migraine prophylaxis, and nocturnal enuresis in children.

Amitriptyline Hydrochloride is a prototype dibenzocycloheptadiene tricyclic antidepressant (TCA) on the WHO Model List of Essential Medicines. It inhibits the presynaptic neuronal reuptake of norepinephrine and serotonin, while also antagonizing muscarinic, histaminergic H1, and alpha-1 adrenergic receptors, and blocking neuronal sodium channels. Indicated for major depressive disorder, neuropathic pain (diabetic neuropathy, post-herpetic neuralgia), chronic tension-type headache and migraine prophylaxis, and nocturnal enuresis in children.

Amitriptyline Hydrochloride is a prototype dibenzocycloheptadiene tricyclic antidepressant (TCA) on the WHO Model List of Essential Medicines. It inhibits the presynaptic neuronal reuptake of norepinephrine and serotonin, while also antagonizing muscarinic, histaminergic H1, and alpha-1 adrenergic receptors, and blocking neuronal sodium channels. Indicated for major depressive disorder, neuropathic pain (diabetic neuropathy, post-herpetic neuralgia), chronic tension-type headache and migraine prophylaxis, and nocturnal enuresis in children.

Chlordiazepoxide and Amitriptyline is a classic psychotropic formulation combining a benzodiazepine with a tricyclic antidepressant (TCA). Chlordiazepoxide provides prompt reduction of psychic tension, anxiety, and agitation via GABAA receptor enhancement, while amitriptyline inhibits the neuronal reuptake of norepinephrine and serotonin to resolve underlying depressive illness. Indicated for moderate-to-severe depression associated with prominent anxiety, agitation, and insomnia.

Amoxapine is a tricyclic dibenzoxazepine antidepressant. In addition to inhibiting norepinephrine and serotonin reuptake, its active 7-hydroxy metabolite produces significant blockade of dopamine D2 receptors, conferring unique antipsychotic properties. Indicated for major depressive disorder with psychotic features (delusional depression) and neurotic depression.

Amoxapine is a tricyclic dibenzoxazepine antidepressant. In addition to inhibiting norepinephrine and serotonin reuptake, its active 7-hydroxy metabolite produces significant blockade of dopamine D2 receptors, conferring unique antipsychotic properties. Indicated for major depressive disorder with psychotic features (delusional depression) and neurotic depression.

Aripiprazole is a third-generation quinolinone atypical antipsychotic functioning as a dopamine-serotonin system stabilizer. It acts as a partial agonist at dopamine D2 and D3 receptors and serotonin 5-HT1A receptors, and an antagonist at 5-HT2A receptors. By acting as a partial agonist, it buffers hyperactive dopamine in mesolimbic circuits (alleviating positive symptoms) while supporting dopamine activity in mesocortical circuits (improving negative symptoms and avoiding parkinsonism and hyperprolactinemia). Indicated for schizophrenia, acute manic/mixed bipolar episodes, adjunctive treatment in major depression, and Tourette's disorder.

Aripiprazole is a third-generation quinolinone atypical antipsychotic functioning as a dopamine-serotonin system stabilizer. It acts as a partial agonist at dopamine D2 and D3 receptors and serotonin 5-HT1A receptors, and an antagonist at 5-HT2A receptors. By acting as a partial agonist, it buffers hyperactive dopamine in mesolimbic circuits (alleviating positive symptoms) while supporting dopamine activity in mesocortical circuits (improving negative symptoms and avoiding parkinsonism and hyperprolactinemia). Indicated for schizophrenia, acute manic/mixed bipolar episodes, adjunctive treatment in major depression, and Tourette's disorder.

Aripiprazole is a third-generation quinolinone atypical antipsychotic functioning as a dopamine-serotonin system stabilizer. It acts as a partial agonist at dopamine D2 and D3 receptors and serotonin 5-HT1A receptors, and an antagonist at 5-HT2A receptors. By acting as a partial agonist, it buffers hyperactive dopamine in mesolimbic circuits (alleviating positive symptoms) while supporting dopamine activity in mesocortical circuits (improving negative symptoms and avoiding parkinsonism and hyperprolactinemia). Indicated for schizophrenia, acute manic/mixed bipolar episodes, adjunctive treatment in major depression, and Tourette's disorder.

Aripiprazole is a third-generation quinolinone atypical antipsychotic functioning as a dopamine-serotonin system stabilizer. It acts as a partial agonist at dopamine D2 and D3 receptors and serotonin 5-HT1A receptors, and an antagonist at 5-HT2A receptors. By acting as a partial agonist, it buffers hyperactive dopamine in mesolimbic circuits (alleviating positive symptoms) while supporting dopamine activity in mesocortical circuits (improving negative symptoms and avoiding parkinsonism and hyperprolactinemia). Indicated for schizophrenia, acute manic/mixed bipolar episodes, adjunctive treatment in major depression, and Tourette's disorder.

Aripiprazole is a third-generation quinolinone atypical antipsychotic functioning as a dopamine-serotonin system stabilizer. It acts as a partial agonist at dopamine D2 and D3 receptors and serotonin 5-HT1A receptors, and an antagonist at 5-HT2A receptors. By acting as a partial agonist, it buffers hyperactive dopamine in mesolimbic circuits (alleviating positive symptoms) while supporting dopamine activity in mesocortical circuits (improving negative symptoms and avoiding parkinsonism and hyperprolactinemia). Indicated for schizophrenia, acute manic/mixed bipolar episodes, adjunctive treatment in major depression, and Tourette's disorder.

Aripiprazole is a third-generation quinolinone atypical antipsychotic functioning as a dopamine-serotonin system stabilizer. It acts as a partial agonist at dopamine D2 and D3 receptors and serotonin 5-HT1A receptors, and an antagonist at 5-HT2A receptors. By acting as a partial agonist, it buffers hyperactive dopamine in mesolimbic circuits (alleviating positive symptoms) while supporting dopamine activity in mesocortical circuits (improving negative symptoms and avoiding parkinsonism and hyperprolactinemia). Indicated for schizophrenia, acute manic/mixed bipolar episodes, adjunctive treatment in major depression, and Tourette's disorder.

Bromocriptine Mesylate is a semisynthetic ergot alkaloid derivative that acts as a potent dopamine D2 receptor agonist and partial D1 receptor antagonist. In the tuberoinfundibular pathway, it inhibits pituitary prolactin secretion; in the striatum, it stimulates dopamine receptors to improve motor deficits. Indicated for hyperprolactinemia-associated disorders (amenorrhea, galactorrhea, prolactin-secreting adenomas), acromegaly, and Parkinson's disease.

Bupropion Hydrochloride is a monocyclic aminoketone antidepressant that acts as a dual norepinephrine and dopamine reuptake inhibitor (NDRI). It does not affect serotonin or monoamine oxidase, and lacks anticholinergic, sedative, and sexual side effects common to SSRIs. Prolonged-release tablets provide sustained plasma levels. Indicated for major depressive disorder, seasonal affective disorder, and smoking cessation aid.

Chlordiazepoxide is the historical first-discovered benzodiazepine. It acts by binding to stereospecific GABAA receptors in the central nervous system, enhancing chloride ion channel opening and augmenting GABA-mediated neuronal inhibition. Possesses active metabolites with a long elimination half-life. Indicated for short-term relief of severe anxiety disorders and acute management of alcohol withdrawal symptoms.

Chlorpromazine is the historic prototype aliphatic phenothiazine first-generation typical antipsychotic on the WHO Model List of Essential Medicines. It blocks postsynaptic dopamine D2 receptors in the mesolimbic pathway, while also producing strong blockade of alpha-1 adrenergic, histaminergic H1, and muscarinic receptors, causing marked sedation and autonomic stabilization. Indicated for schizophrenia, acute manic excitement, severe behavioral problems, intractable hiccups, and acute porphyria.

Chlorpromazine is the historic prototype aliphatic phenothiazine first-generation typical antipsychotic on the WHO Model List of Essential Medicines. It blocks postsynaptic dopamine D2 receptors in the mesolimbic pathway, while also producing strong blockade of alpha-1 adrenergic, histaminergic H1, and muscarinic receptors, causing marked sedation and autonomic stabilization. Indicated for schizophrenia, acute manic excitement, severe behavioral problems, intractable hiccups, and acute porphyria.

Chlorpromazine is the historic prototype aliphatic phenothiazine first-generation typical antipsychotic on the WHO Model List of Essential Medicines. It blocks postsynaptic dopamine D2 receptors in the mesolimbic pathway, while also producing strong blockade of alpha-1 adrenergic, histaminergic H1, and muscarinic receptors, causing marked sedation and autonomic stabilization. Indicated for schizophrenia, acute manic excitement, severe behavioral problems, intractable hiccups, and acute porphyria.

Cinnarizine and Dimenhydrinate is a dual-target vestibular formulation. Cinnarizine acts as a selective T-type calcium channel blocker, inhibiting calcium influx into vestibular sensory hair cells and dampening labyrinthine hyper-reactivity, while dimenhydrinate (diphenhydramine-theoclate salt) blocks H1 receptors in the vestibular nuclei and solitary tract, suppressing the vegetative emetic reflex. Together, they provide synergistic peripheral and central vestibular suppression. Indicated for the symptomatic treatment of various origins of vertigo in adults.

Citalopram is a racemic bicyclic phthalane derivative selective serotonin reuptake inhibitor (SSRI). It potently and selectively blocks the neuronal reuptake of serotonin (5-HT) in the central nervous system, enhancing serotonergic neurotransmission. Indicated for the treatment of major depressive disorder.

Citicoline (Cytidine 5'-diphosphocholine / CDP-Choline) is a physiological intermediate in the biosynthesis of phosphatidylcholine, the major phospholipid component of neuronal membranes. It repairs damaged neuronal membranes, accelerates reabsorption of cerebral edema, inhibits free fatty acid release, and promotes acetylcholine and dopamine synthesis in the brain. Indicated for acute and subacute ischemic stroke recovery, traumatic brain injury (TBI), cognitive impairment, and vascular dementia.

Clonazepam is a long-acting benzodiazepine with potent anticonvulsant, muscle-relaxant, and anxiolytic actions on the WHO Model List of Essential Medicines. It allosterically modulates GABAA receptors, increasing frequency of chloride channel opening and dampening epileptic foci in the cortex and limbic system. Indicated for panic disorder with or without agoraphobia, Lennox-Gastaut syndrome, myoclonic and akinetic seizures, and absence seizures refractory to succinimides.

Clomipramine Hydrochloride is a chlorinated tricyclic antidepressant with exceptionally potent and selective serotonin reuptake inhibition compared to other TCAs. Its demethylated metabolite acts as a norepinephrine reuptake inhibitor. Considered the gold-standard pharmacological agent for severe obsessive-compulsive disorder (OCD). Also indicated for treatment-resistant depression, panic disorder, and cataplexy associated with narcolepsy.

Clomipramine Hydrochloride is a chlorinated tricyclic antidepressant with exceptionally potent and selective serotonin reuptake inhibition compared to other TCAs. Its demethylated metabolite acts as a norepinephrine reuptake inhibitor. Considered the gold-standard pharmacological agent for severe obsessive-compulsive disorder (OCD). Also indicated for treatment-resistant depression, panic disorder, and cataplexy associated with narcolepsy.

Clomipramine Hydrochloride is a chlorinated tricyclic antidepressant with exceptionally potent and selective serotonin reuptake inhibition compared to other TCAs. Its demethylated metabolite acts as a norepinephrine reuptake inhibitor. Considered the gold-standard pharmacological agent for severe obsessive-compulsive disorder (OCD). Also indicated for treatment-resistant depression, panic disorder, and cataplexy associated with narcolepsy.

Clozapine is a dibenzodiazepine prototype atypical antipsychotic on the WHO Model List of Essential Medicines. It possesses weak affinity for dopamine D2 receptors and potent blockade of D4, 5-HT2A, alpha-1, and muscarinic receptors. Demonstrates unique superiority in reducing suicidal behavior and treating refractory psychosis without producing extrapyramidal symptoms or tardive dyskinesia. Strictly reserved for treatment-resistant schizophrenia and reducing suicidal behavior in schizophrenia or schizoaffective disorder.

Clozapine is a dibenzodiazepine prototype atypical antipsychotic on the WHO Model List of Essential Medicines. It possesses weak affinity for dopamine D2 receptors and potent blockade of D4, 5-HT2A, alpha-1, and muscarinic receptors. Demonstrates unique superiority in reducing suicidal behavior and treating refractory psychosis without producing extrapyramidal symptoms or tardive dyskinesia. Strictly reserved for treatment-resistant schizophrenia and reducing suicidal behavior in schizophrenia or schizoaffective disorder.

Clozapine is a dibenzodiazepine prototype atypical antipsychotic on the WHO Model List of Essential Medicines. It possesses weak affinity for dopamine D2 receptors and potent blockade of D4, 5-HT2A, alpha-1, and muscarinic receptors. Demonstrates unique superiority in reducing suicidal behavior and treating refractory psychosis without producing extrapyramidal symptoms or tardive dyskinesia. Strictly reserved for treatment-resistant schizophrenia and reducing suicidal behavior in schizophrenia or schizoaffective disorder.

Diazepam is a prototype long-acting 1,4-benzodiazepine on the WHO Model List of Essential Medicines. It binds to the GABAA receptor complex in the limbic system, thalamus, and hypothalamus, facilitating GABA-mediated inhibitory neurotransmission. Possesses an active desmethyldiazepam metabolite with a prolonged elimination half-life (up to 100 hours). Indicated for management of anxiety disorders, acute alcohol withdrawal syndrome (delirium tremens), skeletal muscle spasm, and status epilepticus.

Diazepam is a prototype long-acting 1,4-benzodiazepine on the WHO Model List of Essential Medicines. It binds to the GABAA receptor complex in the limbic system, thalamus, and hypothalamus, facilitating GABA-mediated inhibitory neurotransmission. Possesses an active desmethyldiazepam metabolite with a prolonged elimination half-life (up to 100 hours). Indicated for management of anxiety disorders, acute alcohol withdrawal syndrome (delirium tremens), skeletal muscle spasm, and status epilepticus.

Doxepin Capsules 10mg is an evidence-based neuropsychiatric and central nervous system formulation. It acts by modulating neuronal neurotransmission, receptor kinetics, or ion channel conductance to manage neurological and mental health disorders.

Doxepin Capsules 25mg is an evidence-based neuropsychiatric and central nervous system formulation. It acts by modulating neuronal neurotransmission, receptor kinetics, or ion channel conductance to manage neurological and mental health disorders.

Doxepin Capsules 75mg is an evidence-based neuropsychiatric and central nervous system formulation. It acts by modulating neuronal neurotransmission, receptor kinetics, or ion channel conductance to manage neurological and mental health disorders.

Duloxetine is a potent, balanced dual serotonin and norepinephrine reuptake inhibitor (SNRI). It inhibits both 5-HT and NE reuptake in the central nervous system, boosting descending inhibitory pain pathways and elevating mood. Gastro-resistant formulation protects the acid-labile drug from gastric degradation. Indicated for major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain.

Escitalopram is the therapeutically active S-enantiomer of citalopram and the most selective serotonin reuptake inhibitor (SSRI) available. It binds allosterically to the primary site of the human serotonin transporter (SERT), potently inhibiting serotonin reuptake into presynaptic terminals without appreciable affinity for dopamine or norepinephrine transporters or cholinergic/histaminergic receptors. Indicated for major depressive disorder (MDD) and generalized anxiety disorder (GAD).

Etizolam is a thienodiazepine derivative structurally related to benzodiazepines. It acts as a potent full agonist at the GABAA receptor, producing significant anxiolytic, sedative-hypnotic, anticonvulsant, and muscle-relaxant actions with 6- to 10-fold higher potency than diazepam. Indicated for short-term management of generalized anxiety disorder, panic disorder, and insomnia associated with anxiety.

Lamotrigine is a phenyltriazine antiepileptic and mood stabilizer on the WHO Model List of Essential Medicines. It use- and voltage-dependently blocks voltage-gated sodium channels, suppressing the sustained repetitive firing of neurons and inhibiting the pathological release of the excitatory neurotransmitter glutamate. Indicated for focal seizures, generalized tonic-clonic seizures, Lennox-Gastaut syndrome, and maintenance treatment of bipolar I disorder to delay mood episodes.

Lamotrigine is a phenyltriazine antiepileptic and mood stabilizer on the WHO Model List of Essential Medicines. It use- and voltage-dependently blocks voltage-gated sodium channels, suppressing the sustained repetitive firing of neurons and inhibiting the pathological release of the excitatory neurotransmitter glutamate. Indicated for focal seizures, generalized tonic-clonic seizures, Lennox-Gastaut syndrome, and maintenance treatment of bipolar I disorder to delay mood episodes.

Mirtazapine is a noradrenergic and specific serotonergic antidepressant (NaSSA). It antagonizes presynaptic alpha-2 auto- and hetero-receptors, boosting central release of both norepinephrine and serotonin. It selectively blocks postsynaptic 5-HT2 and 5-HT3 receptors (sparing patients from SSRI-associated nausea, anxiety, and sexual dysfunction) while enhancing 5-HT1A-mediated transmission. It is also a potent H1 antagonist. Indicated for major depressive disorder, particularly in patients with severe insomnia, anxiety, and weight loss.

Fluoxetine Hydrochloride is a prototype selective serotonin reuptake inhibitor (SSRI) on the WHO Model List of Essential Medicines. It blocks the presynaptic serotonin transporter (SERT) and possesses a long elimination half-life (1-3 days for parent drug, 7-15 days for active norfluoxetine), providing a built-in buffer against abrupt discontinuation syndrome. Also displays mild 5-HT2C antagonism, contributing to energizing/activating effects. Indicated for major depressive disorder, obsessive-compulsive disorder (OCD), bulimia nervosa, and panic disorder.

Phenytoin is a classic hydantoin antiepileptic on the WHO Model List of Essential Medicines. It voltage- and use-dependently promotes sodium channel inactivation, stabilizing neuronal membranes and limiting the spread of seizure activity from epileptic foci. Exhibits non-linear (Michaelis-Menten) saturation pharmacokinetics, where small dose increases can produce disproportionate, toxic rises in plasma concentrations. Indicated for tonic-clonic (grand mal) seizures, focal seizures, and prevention/treatment of seizures following neurosurgery.

Clonazepam is a long-acting benzodiazepine with potent anticonvulsant, muscle-relaxant, and anxiolytic actions on the WHO Model List of Essential Medicines. It allosterically modulates GABAA receptors, increasing frequency of chloride channel opening and dampening epileptic foci in the cortex and limbic system. Indicated for panic disorder with or without agoraphobia, Lennox-Gastaut syndrome, myoclonic and akinetic seizures, and absence seizures refractory to succinimides.

Risperidone is a benzisoxazole second-generation atypical antipsychotic on the WHO Model List of Essential Medicines. It possesses high-affinity antagonism at serotonin 5-HT2A and dopamine D2 receptors, as well as alpha-1 and alpha-2 adrenergic and H1 receptors. Indicated for schizophrenia in adults and adolescents, acute mania in bipolar I disorder, and irritability/severe aggression associated with autistic disorder in children.

Risperidone is a benzisoxazole second-generation atypical antipsychotic on the WHO Model List of Essential Medicines. It possesses high-affinity antagonism at serotonin 5-HT2A and dopamine D2 receptors, as well as alpha-1 and alpha-2 adrenergic and H1 receptors. Indicated for schizophrenia in adults and adolescents, acute mania in bipolar I disorder, and irritability/severe aggression associated with autistic disorder in children.

Tolperisone Tablet 150mg is an evidence-based neuropsychiatric and central nervous system formulation. It acts by modulating neuronal neurotransmission, receptor kinetics, or ion channel conductance to manage neurological and mental health disorders.

Ropinirole Tablets 1 mg is an evidence-based neuropsychiatric and central nervous system formulation. It acts by modulating neuronal neurotransmission, receptor kinetics, or ion channel conductance to manage neurological and mental health disorders.

Ropinirole Tablets 2 mg is an evidence-based neuropsychiatric and central nervous system formulation. It acts by modulating neuronal neurotransmission, receptor kinetics, or ion channel conductance to manage neurological and mental health disorders.

Ropinirole Tablets 4 mg is an evidence-based neuropsychiatric and central nervous system formulation. It acts by modulating neuronal neurotransmission, receptor kinetics, or ion channel conductance to manage neurological and mental health disorders.

Sodium Valproate / Divalproex Sodium is a broad-spectrum antiepileptic and mood stabilizer on the WHO Model List of Essential Medicines. It increases brain gamma-aminobutyric acid (GABA) levels by inhibiting GABA transaminase and succinic semialdehyde dehydrogenase, while blocking voltage-gated T-type calcium channels and sustained repetitive firing of voltage-sensitive sodium channels. Indicated for generalized and focal epilepsy (absence, myoclonic, tonic-clonic seizures), acute manic episodes in bipolar disorder, and migraine prophylaxis.

Lignocaine (Lidocaine) Hydrochloride is the gold-standard amino-amide local anesthetic and Class Ib antiarrhythmic agent on the WHO Model List of Essential Medicines. It reversibly blocks voltage-gated sodium channels in neuronal cell membranes, stopping the generation and propagation of pain signals. When combined with Adrenaline (Epinephrine 1:80,000), localized vasoconstriction reduces surgical bleeding, slows systemic anesthetic absorption, and doubles the duration of local anesthesia. Indicated for infiltration anesthesia, regional nerve blocks, epidural anesthesia, and treatment of acute ventricular arrhythmias.

Carbamazepine is an iminostilbene dibenzazepine antiepileptic on the WHO Model List of Essential Medicines. It voltage- and use-dependently blocks neuronal voltage-gated sodium channels, preventing repetitive neuronal firing and inhibiting spread of seizure discharges. It is the gold-standard first-line agent for trigeminal neuralgia. Indicated for focal (partial) seizures, generalized tonic-clonic seizures, trigeminal neuralgia, and acute mania/bipolar maintenance.

Levodopa and Carbidopa is the gold-standard cornerstone treatment for Parkinson's disease on the WHO Model List of Essential Medicines. Levodopa crosses the blood-brain barrier via large neutral amino acid transporters and is decarboxylated by central DOPA decarboxylase into active dopamine in the striatum. Carbidopa does not penetrate the blood-brain barrier; it inhibits peripheral decarboxylation, preventing peripheral dopamine-mediated nausea and cardiovascular toxicity while increasing central levodopa availability tenfold. Indicated for Parkinson's disease and post-encephalitic parkinsonism.

Sodium Valproate / Divalproex Sodium is a broad-spectrum antiepileptic and mood stabilizer on the WHO Model List of Essential Medicines. It increases brain gamma-aminobutyric acid (GABA) levels by inhibiting GABA transaminase and succinic semialdehyde dehydrogenase, while blocking voltage-gated T-type calcium channels and sustained repetitive firing of voltage-sensitive sodium channels. Indicated for generalized and focal epilepsy (absence, myoclonic, tonic-clonic seizures), acute manic episodes in bipolar disorder, and migraine prophylaxis.

Dosulepin (Dothiepin) Hydrochloride is a thio-derivative tricyclic antidepressant. It blocks the reuptake of norepinephrine and serotonin while exerting significant central sedative and anxiolytic actions via H1 and 5-HT2 antagonism. Indicated for major depressive illness, particularly when associated with prominent anxiety, agitation, and sleep disturbance.

Etizolam and Propranolol is a psychotropic and autonomic regulator combination pairing a thienodiazepine with a non-selective beta-blocker. Etizolam acts as a full agonist at central GABAA receptors to suppress emotional distress and anticipatory anxiety, while propranolol blocks peripheral beta-adrenergic receptors to eliminate somatic symptoms (tachycardia, palpitations, sweating, tremors). Indicated for situational anxiety, autonomic anxiety manifestations, panic disorder, and tension headache.

Lacosamide is a functionalized amino acid antiepileptic. It selectively enhances the slow inactivation of voltage-gated sodium channels, differing from traditional sodium channel blockers that target fast inactivation, thereby normalizing hyper-excitable neuronal membranes without disrupting physiological activity. Indicated as monotherapy and adjunctive therapy for partial-onset seizures in patients with epilepsy.

Nortriptyline Hydrochloride is a secondary amine tricyclic antidepressant and the active demethylated metabolite of amitriptyline. It selectively inhibits the reuptake of norepinephrine over serotonin, offering effective antidepressant and neuropathic analgesia with significantly less sedation, anticholinergic burden, and orthostatic hypotension than amitriptyline. Indicated for major depressive disorder and chronic neuropathic pain syndromes.

Oxcarbazepine is a 10-keto structural analogue of carbamazepine. It is rapidly and completely reduced by cytosolic arylketone reductase into its active 10-monohydroxy metabolite (MHD; licarbazepine), which blocks voltage-sensitive sodium channels and high-voltage-activated calcium channels. Unlike carbamazepine, it does not form a toxic epoxide intermediate and does not undergo hepatic auto-induction. Indicated as monotherapy or adjunctive therapy for partial-onset seizures with or without secondary generalization.

Pregabalin is an analogue of gamma-aminobutyric acid (GABA) that acts as a potent ligand at the alpha-2-delta auxiliary subunit of presynaptic voltage-gated calcium channels in the central nervous system. By reducing calcium influx into hyper-excited neurons, it curbs the pathological release of glutamate, substance P, and calcitonin gene-related peptide. Indicated for neuropathic pain associated with diabetic peripheral neuropathy, post-herpetic neuralgia, fibromyalgia, generalized anxiety disorder (GAD), and adjunctive therapy for partial-onset seizures.

Pregabalin is an analogue of gamma-aminobutyric acid (GABA) that acts as a potent ligand at the alpha-2-delta auxiliary subunit of presynaptic voltage-gated calcium channels in the central nervous system. By reducing calcium influx into hyper-excited neurons, it curbs the pathological release of glutamate, substance P, and calcitonin gene-related peptide. Indicated for neuropathic pain associated with diabetic peripheral neuropathy, post-herpetic neuralgia, fibromyalgia, generalized anxiety disorder (GAD), and adjunctive therapy for partial-onset seizures.

Pyridostigmine Bromide is a reversible carbamate quaternary ammonium acetylcholinesterase inhibitor on the WHO Model List of Essential Medicines. It inhibits the enzymatic degradation of acetylcholine at the neuromuscular junction, prolonging and amplifying nicotinic receptor activation. Its quaternary structure prevents blood-brain barrier penetration, focusing action on peripheral muscles without central toxicity. Indicated for the symptomatic treatment of myasthenia gravis and reversal of non-depolarizing neuromuscular block.

Oxcarbazepine is a 10-keto structural analogue of carbamazepine. It is rapidly and completely reduced by cytosolic arylketone reductase into its active 10-monohydroxy metabolite (MHD; licarbazepine), which blocks voltage-sensitive sodium channels and high-voltage-activated calcium channels. Unlike carbamazepine, it does not form a toxic epoxide intermediate and does not undergo hepatic auto-induction. Indicated as monotherapy or adjunctive therapy for partial-onset seizures with or without secondary generalization.

Oxcarbazepine is a 10-keto structural analogue of carbamazepine. It is rapidly and completely reduced by cytosolic arylketone reductase into its active 10-monohydroxy metabolite (MHD; licarbazepine), which blocks voltage-sensitive sodium channels and high-voltage-activated calcium channels. Unlike carbamazepine, it does not form a toxic epoxide intermediate and does not undergo hepatic auto-induction. Indicated as monotherapy or adjunctive therapy for partial-onset seizures with or without secondary generalization.

Paroxetine is a phenylpiperidine-derivative selective serotonin reuptake inhibitor (SSRI) with the highest affinity for SERT among all SSRIs. It also exhibits mild anticholinergic and nitric oxide synthase-inhibiting properties. Prolonged-release formulation ensures gradual drug release over 24 hours, mitigating peak-related gastrointestinal and sedative adverse effects. Indicated for major depressive disorder, panic disorder, social anxiety disorder, generalized anxiety disorder, and PTSD.

Paroxetine is a phenylpiperidine-derivative selective serotonin reuptake inhibitor (SSRI) with the highest affinity for SERT among all SSRIs. It also exhibits mild anticholinergic and nitric oxide synthase-inhibiting properties. Prolonged-release formulation ensures gradual drug release over 24 hours, mitigating peak-related gastrointestinal and sedative adverse effects. Indicated for major depressive disorder, panic disorder, social anxiety disorder, generalized anxiety disorder, and PTSD.

Pramipexole is a non-ergoline dopamine agonist with high relative intrinsic activity and selectivity for dopamine D2, D3, and D4 receptor subtypes, with preferential affinity for D3 receptors in the mesolimbic system. It stimulates striatal dopamine receptors directly, bypassing degenerating nigrostriatal neurons. Indicated for the treatment of signs and symptoms of idiopathic Parkinson's disease (as monotherapy in early disease or adjunct to levodopa) and moderate-to-severe primary Restless Legs Syndrome (RLS).

Risperidone is a benzisoxazole second-generation atypical antipsychotic on the WHO Model List of Essential Medicines. It possesses high-affinity antagonism at serotonin 5-HT2A and dopamine D2 receptors, as well as alpha-1 and alpha-2 adrenergic and H1 receptors. Indicated for schizophrenia in adults and adolescents, acute mania in bipolar I disorder, and irritability/severe aggression associated with autistic disorder in children.

Ropinirole Tablets 0.25mg is an evidence-based neuropsychiatric and central nervous system formulation. It acts by modulating neuronal neurotransmission, receptor kinetics, or ion channel conductance to manage neurological and mental health disorders.

Selegiline Hydrochloride (L-deprenyl) is an irreversible, selective inhibitor of monoamine oxidase type B (MAO-B). By inhibiting dopamine catabolism in the brain, it prolongs and potentiates the therapeutic action of endogenous and exogenous dopamine. Indicated as adjunctive therapy in Parkinson's disease patients being treated with levodopa/carbidopa who exhibit deterioration in the quality of response.

Ziprasidone is an atypical antipsychotic featuring a high 5-HT2A/D2 receptor binding ratio, potent 5-HT1A agonism, 5-HT1D and 5-HT2C antagonism, and moderate inhibition of synaptic serotonin and norepinephrine reuptake. Demonstrates very low propensity for weight gain, diabetes, and hyperlipidemia. Indicated for schizophrenia and acute manic or mixed episodes in bipolar I disorder.

Ziprasidone is an atypical antipsychotic featuring a high 5-HT2A/D2 receptor binding ratio, potent 5-HT1A agonism, 5-HT1D and 5-HT2C antagonism, and moderate inhibition of synaptic serotonin and norepinephrine reuptake. Demonstrates very low propensity for weight gain, diabetes, and hyperlipidemia. Indicated for schizophrenia and acute manic or mixed episodes in bipolar I disorder.

Midazolam is an ultra-short-acting imidazobenzodiazepine with rapid onset and potent sedative, anxiolytic, amnesic, and anticonvulsant properties. It enhances GABAA receptor opening, depressing the central nervous system. Indicated parenterally for pre-operative sedation, conscious sedation during diagnostic/surgical procedures, induction of general anesthesia, and status epilepticus in intensive care units.

Nicotine Polacrilex (Chewing Gum / Orally Disintegrating Strips) is a form of Nicotine Replacement Therapy (NRT) on the WHO Model List of Essential Medicines. It delivers controlled, low doses of medicinal nicotine systemically across the buccal mucosa without the carcinogenic tars, carbon monoxide, or combustion toxins of tobacco smoke, binding to nicotinic acetylcholine receptors in the brain to relieve withdrawal symptoms and craving. Indicated as an aid in smoking cessation and tobacco harm reduction.

Nicotine Polacrilex (Chewing Gum / Orally Disintegrating Strips) is a form of Nicotine Replacement Therapy (NRT) on the WHO Model List of Essential Medicines. It delivers controlled, low doses of medicinal nicotine systemically across the buccal mucosa without the carcinogenic tars, carbon monoxide, or combustion toxins of tobacco smoke, binding to nicotinic acetylcholine receptors in the brain to relieve withdrawal symptoms and craving. Indicated as an aid in smoking cessation and tobacco harm reduction.

Pregabalin and Duloxetine is a synergistic dual-mechanism neuro-analgesic formulation. Pregabalin reduces presynaptic excitatory neurotransmitter release by modulating neuronal voltage-gated calcium channels, while duloxetine, a potent serotonin and noradrenaline reuptake inhibitor (SNRI), amplifies descending central monoaminergic inhibitory pain pathways. Indicated for refractory peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain.

Pregabalin and Duloxetine is a synergistic dual-mechanism neuro-analgesic formulation. Pregabalin reduces presynaptic excitatory neurotransmitter release by modulating neuronal voltage-gated calcium channels, while duloxetine, a potent serotonin and noradrenaline reuptake inhibitor (SNRI), amplifies descending central monoaminergic inhibitory pain pathways. Indicated for refractory peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain.

Pregabalin and Duloxetine is a synergistic dual-mechanism neuro-analgesic formulation. Pregabalin reduces presynaptic excitatory neurotransmitter release by modulating neuronal voltage-gated calcium channels, while duloxetine, a potent serotonin and noradrenaline reuptake inhibitor (SNRI), amplifies descending central monoaminergic inhibitory pain pathways. Indicated for refractory peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain.

Acamprosate Calcium (calcium bis-acetylhomotaurinate) is a neuromodulator on the WHO Model List of Essential Medicines for alcohol dependence. Chronic alcohol exposure disrupts the balance between central excitation and inhibition; acamprosate restores this equilibrium by antagonizing hyperactive NMDA glutamate receptors and modulating GABAA neurotransmission, substantially reducing post-abstinence neurobiological craving and withdrawal distress. Indicated for the maintenance of abstinence from alcohol in alcohol-dependent patients.

Modafinil is an atypical wakefulness-promoting agent. Unlike classical amphetamines, it acts as a selective, low-affinity dopamine transporter (DAT) inhibitor while stimulating hypocretin/orexin, histamine, and alpha-1 adrenergic systems in the hypothalamus and tuberomammillary nucleus, promoting alertness without peripheral sympathomimetic overstimulation or rebound hypersomnolence. Indicated for excessive daytime sleepiness associated with narcolepsy, obstructive sleep apnea (OSA), and shift work sleep disorder (SWSD).

Modafinil is an atypical wakefulness-promoting agent. Unlike classical amphetamines, it acts as a selective, low-affinity dopamine transporter (DAT) inhibitor while stimulating hypocretin/orexin, histamine, and alpha-1 adrenergic systems in the hypothalamus and tuberomammillary nucleus, promoting alertness without peripheral sympathomimetic overstimulation or rebound hypersomnolence. Indicated for excessive daytime sleepiness associated with narcolepsy, obstructive sleep apnea (OSA), and shift work sleep disorder (SWSD).

Brivaracetam is a 4-propyl analogue of levetiracetam with 15- to 30-fold higher binding affinity for synaptic vesicle protein 2A (SV2A). It penetrates the blood-brain barrier rapidly and provides potent anticonvulsant activity with potentially fewer neuropsychiatric and behavioral adverse reactions than levetiracetam. Indicated as monotherapy or adjunctive therapy for partial-onset seizures in patients with epilepsy aged 1 month and older.

Clonazepam and Desvenlafaxine Extended-Release pairs an active SNRI metabolite with a long-acting benzodiazepine. Desvenlafaxine inhibits neuronal reuptake of both serotonin and norepinephrine to reverse core neurochemical deficits in depression, while clonazepam mitigates acute agitation, panic, and sleep disturbances during therapy induction. Indicated for major depressive disorder with prominent anxiety and severe somatic distress.

Clonazepam and Desvenlafaxine Extended-Release pairs an active SNRI metabolite with a long-acting benzodiazepine. Desvenlafaxine inhibits neuronal reuptake of both serotonin and norepinephrine to reverse core neurochemical deficits in depression, while clonazepam mitigates acute agitation, panic, and sleep disturbances during therapy induction. Indicated for major depressive disorder with prominent anxiety and severe somatic distress.

Venlafaxine is a bicyclic phenylethylamine serotonin and norepinephrine reuptake inhibitor (SNRI). At lower doses (< 150 mg/day), it acts predominantly as an SSRI; at higher doses, it significantly blocks norepinephrine reuptake, providing dual neurotransmitter elevation. Prolonged-release capsules provide uniform 24-hour plasma levels. Indicated for major depressive disorder, generalized anxiety disorder, social anxiety disorder, and panic disorder.

Venlafaxine is a bicyclic phenylethylamine serotonin and norepinephrine reuptake inhibitor (SNRI). At lower doses (< 150 mg/day), it acts predominantly as an SSRI; at higher doses, it significantly blocks norepinephrine reuptake, providing dual neurotransmitter elevation. Prolonged-release capsules provide uniform 24-hour plasma levels. Indicated for major depressive disorder, generalized anxiety disorder, social anxiety disorder, and panic disorder.

Donepezil and Memantine is a complementary dual-mechanism formulation for moderate-to-severe dementia. Donepezil, a reversible piperidine acetylcholinesterase inhibitor, increases acetylcholine concentrations at cerebral synapses, while memantine, an uncompetitive NMDA receptor antagonist, protects cholinergic neurons against pathological chronic glutamate-mediated excitotoxicity. Indicated for moderate-to-severe dementia of the Alzheimer's type.

Donepezil and Memantine is a complementary dual-mechanism formulation for moderate-to-severe dementia. Donepezil, a reversible piperidine acetylcholinesterase inhibitor, increases acetylcholine concentrations at cerebral synapses, while memantine, an uncompetitive NMDA receptor antagonist, protects cholinergic neurons against pathological chronic glutamate-mediated excitotoxicity. Indicated for moderate-to-severe dementia of the Alzheimer's type.

Etizolam and Propranolol is a psychotropic and autonomic regulator combination pairing a thienodiazepine with a non-selective beta-blocker. Etizolam acts as a full agonist at central GABAA receptors to suppress emotional distress and anticipatory anxiety, while propranolol blocks peripheral beta-adrenergic receptors to eliminate somatic symptoms (tachycardia, palpitations, sweating, tremors). Indicated for situational anxiety, autonomic anxiety manifestations, panic disorder, and tension headache.

Nortriptyline Hydrochloride is a secondary amine tricyclic antidepressant and the active demethylated metabolite of amitriptyline. It selectively inhibits the reuptake of norepinephrine over serotonin, offering effective antidepressant and neuropathic analgesia with significantly less sedation, anticholinergic burden, and orthostatic hypotension than amitriptyline. Indicated for major depressive disorder and chronic neuropathic pain syndromes.

Lithium Carbonate is the classical mood-stabilizing monovalent cation on the WHO Model List of Essential Medicines. It alters neuronal sodium transport, inhibits inositol monophosphatase (depleting free intracellular inositol and dampening phosphoinositide signaling), and inhibits glycogen synthase kinase-3 beta (GSK-3beta), providing neuroprotective neuroplasticity. Indicated for the treatment of acute manic and mixed episodes in bipolar disorder and long-term maintenance therapy to prevent bipolar relapses and decrease suicide risk.

Lorazepam is a high-potency, intermediate-acting 3-hydroxy benzodiazepine on the WHO Model List of Essential Medicines. It enhances GABA-mediated synaptic inhibition by binding to GABAA receptors. Because it undergoes direct hepatic glucuronidation to inactive metabolites without intermediate oxidative CYP450 steps, it is the benzodiazepine of choice in patients with hepatic impairment and the elderly. Indicated for short-term management of severe anxiety, insomnia associated with anxiety, acute status epilepticus, and pre-anesthetic sedation.

Midazolam Nasal Spray is an emergency rescue formulation for acute repetitive seizures and status epilepticus. Delivered across the nasal mucosa, it provides rapid systemic absorption directly into cerebral circulation via the olfactory/trigeminal pathway, bypassing hepatic first-pass metabolism to arrest prolonged convulsions within minutes. Indicated for acute treatment of intermittent, stereotypic episodes of frequent seizure activity in patients with epilepsy.

Modafinil is an atypical wakefulness-promoting agent. Unlike classical amphetamines, it acts as a selective, low-affinity dopamine transporter (DAT) inhibitor while stimulating hypocretin/orexin, histamine, and alpha-1 adrenergic systems in the hypothalamus and tuberomammillary nucleus, promoting alertness without peripheral sympathomimetic overstimulation or rebound hypersomnolence. Indicated for excessive daytime sleepiness associated with narcolepsy, obstructive sleep apnea (OSA), and shift work sleep disorder (SWSD).

Pramipexole is a non-ergoline dopamine agonist with high relative intrinsic activity and selectivity for dopamine D2, D3, and D4 receptor subtypes, with preferential affinity for D3 receptors in the mesolimbic system. It stimulates striatal dopamine receptors directly, bypassing degenerating nigrostriatal neurons. Indicated for the treatment of signs and symptoms of idiopathic Parkinson's disease (as monotherapy in early disease or adjunct to levodopa) and moderate-to-severe primary Restless Legs Syndrome (RLS).

Pramipexole is a non-ergoline dopamine agonist with high relative intrinsic activity and selectivity for dopamine D2, D3, and D4 receptor subtypes, with preferential affinity for D3 receptors in the mesolimbic system. It stimulates striatal dopamine receptors directly, bypassing degenerating nigrostriatal neurons. Indicated for the treatment of signs and symptoms of idiopathic Parkinson's disease (as monotherapy in early disease or adjunct to levodopa) and moderate-to-severe primary Restless Legs Syndrome (RLS).

Procyclidine Hydrochloride is a synthetic anticholinergic agent that blocks central muscarinic acetylcholine receptors, correcting striatal cholinergic overactivity resulting from dopamine depletion. Indicated for idiopathic and post-encephalitic Parkinson's disease, and treatment of neuroleptic-induced extrapyramidal symptoms (acute dystonias, oculogyric crisis, pseudoparkinsonism).

Procyclidine Hydrochloride is a synthetic anticholinergic agent that blocks central muscarinic acetylcholine receptors, correcting striatal cholinergic overactivity resulting from dopamine depletion. Indicated for idiopathic and post-encephalitic Parkinson's disease, and treatment of neuroleptic-induced extrapyramidal symptoms (acute dystonias, oculogyric crisis, pseudoparkinsonism).

Topiramate is a sulfamate-substituted monosaccharide antiepileptic with multiple mechanisms of action. It blocks voltage-dependent sodium channels, potentiates GABA-mediated inhibitory currents at non-benzodiazepine sites, antagonizes AMPA/kainate glutamate receptors, and weakly inhibits carbonic anhydrase isozymes CA-II and CA-IV. Indicated for partial-onset seizures, primary generalized tonic-clonic seizures, Lennox-Gastaut syndrome, and migraine prophylaxis in adults and adolescents.

Topiramate is a sulfamate-substituted monosaccharide antiepileptic with multiple mechanisms of action. It blocks voltage-dependent sodium channels, potentiates GABA-mediated inhibitory currents at non-benzodiazepine sites, antagonizes AMPA/kainate glutamate receptors, and weakly inhibits carbonic anhydrase isozymes CA-II and CA-IV. Indicated for partial-onset seizures, primary generalized tonic-clonic seizures, Lennox-Gastaut syndrome, and migraine prophylaxis in adults and adolescents.

Trazodone Hydrochloride is a triazolopyridine serotonin antagonist and reuptake inhibitor (SARI). At therapeutic doses, it acts as a potent antagonist at postsynaptic 5-HT2A receptors and an antagonist at alpha-1 adrenergic and histamine H1 receptors, with weak inhibition of serotonin reuptake. Indicated for major depressive disorder with comorbid anxiety or insomnia, and widely used off-label as a non-habit-forming sleep aid in depression.

Venlafaxine is a bicyclic phenylethylamine serotonin and norepinephrine reuptake inhibitor (SNRI). At lower doses (< 150 mg/day), it acts predominantly as an SSRI; at higher doses, it significantly blocks norepinephrine reuptake, providing dual neurotransmitter elevation. Prolonged-release capsules provide uniform 24-hour plasma levels. Indicated for major depressive disorder, generalized anxiety disorder, social anxiety disorder, and panic disorder.

Venlafaxine is a bicyclic phenylethylamine serotonin and norepinephrine reuptake inhibitor (SNRI). At lower doses (< 150 mg/day), it acts predominantly as an SSRI; at higher doses, it significantly blocks norepinephrine reuptake, providing dual neurotransmitter elevation. Prolonged-release capsules provide uniform 24-hour plasma levels. Indicated for major depressive disorder, generalized anxiety disorder, social anxiety disorder, and panic disorder.

Venlafaxine is a bicyclic phenylethylamine serotonin and norepinephrine reuptake inhibitor (SNRI). At lower doses (< 150 mg/day), it acts predominantly as an SSRI; at higher doses, it significantly blocks norepinephrine reuptake, providing dual neurotransmitter elevation. Prolonged-release capsules provide uniform 24-hour plasma levels. Indicated for major depressive disorder, generalized anxiety disorder, social anxiety disorder, and panic disorder.

Zonisamide is a 1,2-benzisoxazole derivative antiepileptic. It acts by blocking voltage-dependent sodium channels and reducing inward T-type calcium currents, while exhibiting weak carbonic anhydrase inhibitory activity. Indicated as adjunctive therapy in the treatment of partial-onset seizures in adults.

Zonisamide is a 1,2-benzisoxazole derivative antiepileptic. It acts by blocking voltage-dependent sodium channels and reducing inward T-type calcium currents, while exhibiting weak carbonic anhydrase inhibitory activity. Indicated as adjunctive therapy in the treatment of partial-onset seizures in adults.

Melatonin is a synthetic chronobiotic hormone identical to endogenous pineal melatonin. It acts as an agonist at high-affinity G-protein coupled MT1 and MT2 receptors in the suprachiasmatic nucleus (SCN) of the hypothalamus. Activation of MT1 promotes sleep onset by dampening neuronal firing in the master circadian clock, while MT2 shifts circadian rhythm phase. Indicated for primary insomnia characterized by poor sleep quality in adults aged 55 and older, delayed sleep phase syndrome, and jet lag.

Oxcarbazepine is a 10-keto structural analogue of carbamazepine. It is rapidly and completely reduced by cytosolic arylketone reductase into its active 10-monohydroxy metabolite (MHD; licarbazepine), which blocks voltage-sensitive sodium channels and high-voltage-activated calcium channels. Unlike carbamazepine, it does not form a toxic epoxide intermediate and does not undergo hepatic auto-induction. Indicated as monotherapy or adjunctive therapy for partial-onset seizures with or without secondary generalization.

Levodopa and Carbidopa is the gold-standard cornerstone treatment for Parkinson's disease on the WHO Model List of Essential Medicines. Levodopa crosses the blood-brain barrier via large neutral amino acid transporters and is decarboxylated by central DOPA decarboxylase into active dopamine in the striatum. Carbidopa does not penetrate the blood-brain barrier; it inhibits peripheral decarboxylation, preventing peripheral dopamine-mediated nausea and cardiovascular toxicity while increasing central levodopa availability tenfold. Indicated for Parkinson's disease and post-encephalitic parkinsonism.

Quetiapine Fumarate is a dibenzothiazepine atypical antipsychotic. It exhibits antagonist activity at serotonin 5-HT2A and dopamine D2 receptors, with rapid dissociation from D2 receptors ("hit-and-run" kinetics) which minimizes extrapyramidal symptoms and hyperprolactinemia. Its active metabolite, norquetiapine, potently inhibits norepinephrine reuptake (NET) and acts as a 5-HT1A partial agonist, conferring distinctive antidepressant efficacy. Indicated for schizophrenia, acute manic episodes in bipolar I disorder, bipolar depression, and adjunctive therapy in major depressive disorder.

Vortioxetine is a multimodal serotonergic antidepressant (SMS). It acts as a selective serotonin reuptake inhibitor (SERT inhibition) combined with direct agonist activity at 5-HT1A receptors, partial agonism at 5-HT1B, and antagonist activity at 5-HT1D, 5-HT3, and 5-HT7 receptors. This multimodal receptor profile enhances acetylcholine, noradrenaline, and histamine release, demonstrating notable benefits on depressive cognitive dysfunction. Indicated for major depressive disorder (MDD).

Vortioxetine is a multimodal serotonergic antidepressant (SMS). It acts as a selective serotonin reuptake inhibitor (SERT inhibition) combined with direct agonist activity at 5-HT1A receptors, partial agonism at 5-HT1B, and antagonist activity at 5-HT1D, 5-HT3, and 5-HT7 receptors. This multimodal receptor profile enhances acetylcholine, noradrenaline, and histamine release, demonstrating notable benefits on depressive cognitive dysfunction. Indicated for major depressive disorder (MDD).

Vortioxetine is a multimodal serotonergic antidepressant (SMS). It acts as a selective serotonin reuptake inhibitor (SERT inhibition) combined with direct agonist activity at 5-HT1A receptors, partial agonism at 5-HT1B, and antagonist activity at 5-HT1D, 5-HT3, and 5-HT7 receptors. This multimodal receptor profile enhances acetylcholine, noradrenaline, and histamine release, demonstrating notable benefits on depressive cognitive dysfunction. Indicated for major depressive disorder (MDD).

Clozapine is a dibenzodiazepine prototype atypical antipsychotic on the WHO Model List of Essential Medicines. It possesses weak affinity for dopamine D2 receptors and potent blockade of D4, 5-HT2A, alpha-1, and muscarinic receptors. Demonstrates unique superiority in reducing suicidal behavior and treating refractory psychosis without producing extrapyramidal symptoms or tardive dyskinesia. Strictly reserved for treatment-resistant schizophrenia and reducing suicidal behavior in schizophrenia or schizoaffective disorder.

Citicoline (Cytidine 5'-diphosphocholine / CDP-Choline) is a physiological intermediate in the biosynthesis of phosphatidylcholine, the major phospholipid component of neuronal membranes. It repairs damaged neuronal membranes, accelerates reabsorption of cerebral edema, inhibits free fatty acid release, and promotes acetylcholine and dopamine synthesis in the brain. Indicated for acute and subacute ischemic stroke recovery, traumatic brain injury (TBI), cognitive impairment, and vascular dementia.

Duloxetine is a potent, balanced dual serotonin and norepinephrine reuptake inhibitor (SNRI). It inhibits both 5-HT and NE reuptake in the central nervous system, boosting descending inhibitory pain pathways and elevating mood. Gastro-resistant formulation protects the acid-labile drug from gastric degradation. Indicated for major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain.

Duloxetine is a potent, balanced dual serotonin and norepinephrine reuptake inhibitor (SNRI). It inhibits both 5-HT and NE reuptake in the central nervous system, boosting descending inhibitory pain pathways and elevating mood. Gastro-resistant formulation protects the acid-labile drug from gastric degradation. Indicated for major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain.

Entacapone is a reversible, selective, and peripherally acting catechol-O-methyltransferase (COMT) inhibitor. It blocks the conversion of levodopa to 3-O-methyldopa (3-OMD) in peripheral tissues, leading to sustained plasma levodopa concentrations and greater brain bioavailability. Indicated as an adjunct to levodopa and carbidopa for Parkinson's disease patients experiencing end-of-dose motor fluctuations ("wearing-off").

Etizolam and Escitalopram combines a fast-acting thienodiazepine with a selective serotonin reuptake inhibitor. Etizolam acts rapidly within 30-60 minutes to suppress acute anxiety, muscle tension, and insomnia, while escitalopram normalizes central serotonergic tone to treat chronic depression and anxiety. Indicated for comorbid depression and anxiety, panic disorder, and acute stress disorders.

Etizolam and Escitalopram combines a fast-acting thienodiazepine with a selective serotonin reuptake inhibitor. Etizolam acts rapidly within 30-60 minutes to suppress acute anxiety, muscle tension, and insomnia, while escitalopram normalizes central serotonergic tone to treat chronic depression and anxiety. Indicated for comorbid depression and anxiety, panic disorder, and acute stress disorders.

Etizolam is a thienodiazepine derivative structurally related to benzodiazepines. It acts as a potent full agonist at the GABAA receptor, producing significant anxiolytic, sedative-hypnotic, anticonvulsant, and muscle-relaxant actions with 6- to 10-fold higher potency than diazepam. Indicated for short-term management of generalized anxiety disorder, panic disorder, and insomnia associated with anxiety.

Pregabalin and Etoricoxib pairs a centrally acting alpha-2-delta ligand with a selective cyclooxygenase-2 (COX-2) inhibitor. Pregabalin dampens neuropathic hyperalgesia and central sensitization, while etoricoxib selectively inhibits inducible COX-2, decreasing peripheral prostaglandin synthesis and localized inflammatory pain. Indicated for mixed nociceptive-neuropathic pain syndromes, severe radiculopathy, sciatica, and refractory spondylitis.

Gabapentin and Nortriptyline is a dual-acting neuropathic pain formulation combining a gabapentinoid with a tricyclic antidepressant. Gabapentin decreases excitatory neurotransmitter exocytosis by binding to alpha-2-delta subunits of voltage-gated calcium channels, while nortriptyline blocks presynaptic reuptake of noradrenaline and serotonin, reinforcing endogenous descending spinal analgesia. Indicated for diabetic peripheral neuropathy, post-herpetic neuralgia, and chronic radiculopathy.

Gabapentin, Lignocaine (Lidocaine), and Baclofen topical gel is a localized multi-modal compound for refractory neuropathic and musculoskeletal pain. Gabapentin provides regional neuro-inhibition via calcium channel modulation; lignocaine reversibly blocks neuronal sodium channels to arrest pain impulse conduction; and baclofen activates GABAB receptors, inducing local skeletal muscle relaxation and mitigating spastic myofascial trigger points. Indicated for localized post-herpetic neuralgia, superficial neuropathic pain, and focal myofascial pain syndromes.

Levetiracetam is a pyrrolidone derivative second-generation antiepileptic on the WHO Model List of Essential Medicines. It exhibits a unique mechanism of action, binding stereoselectively to synaptic vesicle protein 2A (SV2A) in presynaptic terminals, modulating exocytosis and restraining pathological vesicle release of excitatory neurotransmitters without affecting normal neurotransmission. Demonstrates near 100% oral bioavailability and minimal hepatic CYP450 metabolism. Indicated as monotherapy and adjunctive therapy for focal seizures, myoclonic seizures in juvenile myoclonic epilepsy, and primary generalized tonic-clonic seizures.

Levodopa, Carbidopa, and Entacapone is a triple-combination antiparkinsonian formulation. Levodopa is the metabolic precursor of dopamine that crosses the blood-brain barrier; carbidopa is a peripheral aromatic L-amino acid decarboxylase (DOPA decarboxylase) inhibitor; and entacapone is a reversible peripheral catechol-O-methyltransferase (COMT) inhibitor. Carbidopa and entacapone block both major peripheral metabolic degradation pathways of levodopa, significantly increasing the plasma half-life and brain delivery of levodopa and smoothing out motor fluctuations. Indicated for Parkinson's disease patients experiencing end-of-dose motor fluctuations ("wearing-off").

Levodopa, Carbidopa, and Entacapone is a triple-combination antiparkinsonian formulation. Levodopa is the metabolic precursor of dopamine that crosses the blood-brain barrier; carbidopa is a peripheral aromatic L-amino acid decarboxylase (DOPA decarboxylase) inhibitor; and entacapone is a reversible peripheral catechol-O-methyltransferase (COMT) inhibitor. Carbidopa and entacapone block both major peripheral metabolic degradation pathways of levodopa, significantly increasing the plasma half-life and brain delivery of levodopa and smoothing out motor fluctuations. Indicated for Parkinson's disease patients experiencing end-of-dose motor fluctuations ("wearing-off").

Levodopa, Carbidopa, and Entacapone is a triple-combination antiparkinsonian formulation. Levodopa is the metabolic precursor of dopamine that crosses the blood-brain barrier; carbidopa is a peripheral aromatic L-amino acid decarboxylase (DOPA decarboxylase) inhibitor; and entacapone is a reversible peripheral catechol-O-methyltransferase (COMT) inhibitor. Carbidopa and entacapone block both major peripheral metabolic degradation pathways of levodopa, significantly increasing the plasma half-life and brain delivery of levodopa and smoothing out motor fluctuations. Indicated for Parkinson's disease patients experiencing end-of-dose motor fluctuations ("wearing-off").

Lignocaine (Lidocaine) and Nifedipine topical cream is a specialized anorectal formulation. Lignocaine reversibly blocks neuronal sodium channels to provide rapid local analgesia, relieving severe anal pain and spasm, while nifedipine, a calcium channel blocker, relaxes the hypertonic internal anal sphincter muscle, reducing resting anal pressure and enhancing local mucosal blood perfusion to promote tissue healing. Indicated for the conservative medical management of acute and chronic anal fissures.

Lignocaine 2.5% & Prilocaine 2.5% Topical Gel (EMLA) is an evidence-based dermatological formulation. It acts by delivering targeted active therapeutic ingredients to cutaneous lesions to relieve skin pathology, restore barrier integrity, and manage dermatoses.

Neostigmine Methylsulphate is a synthetic quaternary ammonium reversible anticholinesterase agent on the WHO Model List of Essential Medicines. It inhibits acetylcholinesterase at the neuromuscular junction and postganglionic parasympathetic synapses, accumulating acetylcholine and competitively displacing non-depolarizing muscle relaxants. Indicated parenterally for the reversal of non-depolarizing neuromuscular blockade post-surgery, myasthenia gravis crisis, and non-obstructive postoperative paralytic ileus/urinary retention.

Neostigmine Methylsulphate is a synthetic quaternary ammonium reversible anticholinesterase agent on the WHO Model List of Essential Medicines. It inhibits acetylcholinesterase at the neuromuscular junction and postganglionic parasympathetic synapses, accumulating acetylcholine and competitively displacing non-depolarizing muscle relaxants. Indicated parenterally for the reversal of non-depolarizing neuromuscular blockade post-surgery, myasthenia gravis crisis, and non-obstructive postoperative paralytic ileus/urinary retention.

Quetiapine Fumarate is a dibenzothiazepine atypical antipsychotic. It exhibits antagonist activity at serotonin 5-HT2A and dopamine D2 receptors, with rapid dissociation from D2 receptors ("hit-and-run" kinetics) which minimizes extrapyramidal symptoms and hyperprolactinemia. Its active metabolite, norquetiapine, potently inhibits norepinephrine reuptake (NET) and acts as a 5-HT1A partial agonist, conferring distinctive antidepressant efficacy. Indicated for schizophrenia, acute manic episodes in bipolar I disorder, bipolar depression, and adjunctive therapy in major depressive disorder.

Rasagiline is a second-generation, irreversible, selective monoamine oxidase type B (MAO-B) inhibitor. It prevents the metabolic breakdown of dopamine in the striatum, increasing synaptic dopamine concentrations without the amphetamine metabolites associated with selegiline. Indicated as initial monotherapy in early Parkinson's disease and as adjunctive therapy to levodopa in advanced disease with motor fluctuations.

Rasagiline is a second-generation, irreversible, selective monoamine oxidase type B (MAO-B) inhibitor. It prevents the metabolic breakdown of dopamine in the striatum, increasing synaptic dopamine concentrations without the amphetamine metabolites associated with selegiline. Indicated as initial monotherapy in early Parkinson's disease and as adjunctive therapy to levodopa in advanced disease with motor fluctuations.

Tranylcypromine is a non-hydrazine, irreversible, non-selective monoamine oxidase inhibitor (MAOI). It binds and covalently inactivates both MAO-A and MAO-B enzymes, preventing the metabolic breakdown of norepinephrine, serotonin, and dopamine throughout the central nervous system. Reserved for severe, treatment-resistant major depression refractory to other classes.

Triclofos Sodium is an orally administered phosphate prodrug of trichloroethanol, the active metabolite of chloral hydrate. It is rapidly hydrolyzed in the intestine and liver to trichloroethanol, which enhances inhibitory GABAergic transmission in the central nervous system, producing rapid, naturalistic sedation without significant respiratory or cardiovascular depression. Indicated for short-term pediatric sedation prior to non-invasive diagnostic procedures (EEG, MRI, CT scans, echocardiograms) and short-term insomnia.

Amisulpride is a substituted benzamide atypical antipsychotic. It acts with high selectivity as an antagonist at presynaptic and postsynaptic dopamine D2 and D3 receptors in the limbic system, with zero affinity for 5-HT, adrenergic, cholinergic, or histaminergic receptors. At low doses (50-300 mg), it preferentially blocks presynaptic autoreceptors, facilitating dopamine release and improving negative and cognitive symptoms; at higher doses (400-800 mg), it blocks postsynaptic D2 receptors to control positive psychotic symptoms. Indicated for schizophrenia with acute psychotic episodes and predominant negative symptoms.

Amisulpride is a substituted benzamide atypical antipsychotic. It acts with high selectivity as an antagonist at presynaptic and postsynaptic dopamine D2 and D3 receptors in the limbic system, with zero affinity for 5-HT, adrenergic, cholinergic, or histaminergic receptors. At low doses (50-300 mg), it preferentially blocks presynaptic autoreceptors, facilitating dopamine release and improving negative and cognitive symptoms; at higher doses (400-800 mg), it blocks postsynaptic D2 receptors to control positive psychotic symptoms. Indicated for schizophrenia with acute psychotic episodes and predominant negative symptoms.

Amisulpride is a substituted benzamide atypical antipsychotic. It acts with high selectivity as an antagonist at presynaptic and postsynaptic dopamine D2 and D3 receptors in the limbic system, with zero affinity for 5-HT, adrenergic, cholinergic, or histaminergic receptors. At low doses (50-300 mg), it preferentially blocks presynaptic autoreceptors, facilitating dopamine release and improving negative and cognitive symptoms; at higher doses (400-800 mg), it blocks postsynaptic D2 receptors to control positive psychotic symptoms. Indicated for schizophrenia with acute psychotic episodes and predominant negative symptoms.

Amisulpride is a substituted benzamide atypical antipsychotic. It acts with high selectivity as an antagonist at presynaptic and postsynaptic dopamine D2 and D3 receptors in the limbic system, with zero affinity for 5-HT, adrenergic, cholinergic, or histaminergic receptors. At low doses (50-300 mg), it preferentially blocks presynaptic autoreceptors, facilitating dopamine release and improving negative and cognitive symptoms; at higher doses (400-800 mg), it blocks postsynaptic D2 receptors to control positive psychotic symptoms. Indicated for schizophrenia with acute psychotic episodes and predominant negative symptoms.

Amisulpride is a substituted benzamide atypical antipsychotic. It acts with high selectivity as an antagonist at presynaptic and postsynaptic dopamine D2 and D3 receptors in the limbic system, with zero affinity for 5-HT, adrenergic, cholinergic, or histaminergic receptors. At low doses (50-300 mg), it preferentially blocks presynaptic autoreceptors, facilitating dopamine release and improving negative and cognitive symptoms; at higher doses (400-800 mg), it blocks postsynaptic D2 receptors to control positive psychotic symptoms. Indicated for schizophrenia with acute psychotic episodes and predominant negative symptoms.

Cariprazine is an advanced third-generation atypical antipsychotic that acts as a potent dopamine D3-preferring D2 partial agonist and 5-HT1A partial agonist. Its 10-fold higher affinity for D3 receptors over D2 provides notable improvements in negative symptoms, cognitive deficits, and mood stability in psychotic illnesses. It features an ultra-long-acting active metabolite (didesmethylcariprazine, DDCAR) with an elimination half-life of 1 to 3 weeks. Indicated for schizophrenia in adults, acute manic/mixed episodes in bipolar I disorder, and bipolar depression.

Cariprazine is an advanced third-generation atypical antipsychotic that acts as a potent dopamine D3-preferring D2 partial agonist and 5-HT1A partial agonist. Its 10-fold higher affinity for D3 receptors over D2 provides notable improvements in negative symptoms, cognitive deficits, and mood stability in psychotic illnesses. It features an ultra-long-acting active metabolite (didesmethylcariprazine, DDCAR) with an elimination half-life of 1 to 3 weeks. Indicated for schizophrenia in adults, acute manic/mixed episodes in bipolar I disorder, and bipolar depression.

Cariprazine is an advanced third-generation atypical antipsychotic that acts as a potent dopamine D3-preferring D2 partial agonist and 5-HT1A partial agonist. Its 10-fold higher affinity for D3 receptors over D2 provides notable improvements in negative symptoms, cognitive deficits, and mood stability in psychotic illnesses. It features an ultra-long-acting active metabolite (didesmethylcariprazine, DDCAR) with an elimination half-life of 1 to 3 weeks. Indicated for schizophrenia in adults, acute manic/mixed episodes in bipolar I disorder, and bipolar depression.

Cariprazine is an advanced third-generation atypical antipsychotic that acts as a potent dopamine D3-preferring D2 partial agonist and 5-HT1A partial agonist. Its 10-fold higher affinity for D3 receptors over D2 provides notable improvements in negative symptoms, cognitive deficits, and mood stability in psychotic illnesses. It features an ultra-long-acting active metabolite (didesmethylcariprazine, DDCAR) with an elimination half-life of 1 to 3 weeks. Indicated for schizophrenia in adults, acute manic/mixed episodes in bipolar I disorder, and bipolar depression.

Cyclobenzaprine Hydrochloride is a centrally acting skeletal muscle relaxant structurally related to tricyclic antidepressants. It acts primarily at the brainstem level to reduce tonic somatic motor activity through descending serotonergic and noradrenergic pathways, relieving acute voluntary muscle spasm without interfering with peripheral muscle function. Indicated for short-term relief of muscle spasm associated with acute, painful musculoskeletal conditions.

Donepezil Hydrochloride is a reversible, non-competitive, highly selective piperidine acetylcholinesterase (AChE) inhibitor on the WHO Model List of Essential Medicines. It increases synaptic acetylcholine availability in the cerebral cortex and hippocampus by inhibiting its breakdown. Indicated for mild, moderate, and severe dementia of the Alzheimer's type.

Donepezil Hydrochloride is a reversible, non-competitive, highly selective piperidine acetylcholinesterase (AChE) inhibitor on the WHO Model List of Essential Medicines. It increases synaptic acetylcholine availability in the cerebral cortex and hippocampus by inhibiting its breakdown. Indicated for mild, moderate, and severe dementia of the Alzheimer's type.

Lurasidone Hydrochloride is a benzoisothiazole second-generation atypical antipsychotic. It acts as an antagonist at dopamine D2 and 5-HT2A receptors, with potent partial agonism at 5-HT1A and high antagonism at 5-HT7 receptors, while lacking anticholinergic and H1 antihistaminic properties, offering an exceptionally clean metabolic profile with minimal weight gain or sedation. Indicated for schizophrenia and depressive episodes associated with bipolar I disorder (bipolar depression).

Lurasidone Hydrochloride is a benzoisothiazole second-generation atypical antipsychotic. It acts as an antagonist at dopamine D2 and 5-HT2A receptors, with potent partial agonism at 5-HT1A and high antagonism at 5-HT7 receptors, while lacking anticholinergic and H1 antihistaminic properties, offering an exceptionally clean metabolic profile with minimal weight gain or sedation. Indicated for schizophrenia and depressive episodes associated with bipolar I disorder (bipolar depression).

Lurasidone Hydrochloride is a benzoisothiazole second-generation atypical antipsychotic. It acts as an antagonist at dopamine D2 and 5-HT2A receptors, with potent partial agonism at 5-HT1A and high antagonism at 5-HT7 receptors, while lacking anticholinergic and H1 antihistaminic properties, offering an exceptionally clean metabolic profile with minimal weight gain or sedation. Indicated for schizophrenia and depressive episodes associated with bipolar I disorder (bipolar depression).

Maraviroc Tablets 150 mg is an evidence-based neuropsychiatric and central nervous system formulation. It acts by modulating neuronal neurotransmission, receptor kinetics, or ion channel conductance to manage neurological and mental health disorders.

Risperidone and Trihexyphenidyl (Benzhexol) is a therapeutic combination designed to provide antipsychotic efficacy while preventing drug-induced movement disorders. Risperidone, a benzisoxazole atypical antipsychotic, blocks dopamine D2 and serotonin 5-HT2A receptors to control psychosis, while trihexyphenidyl, a centrally acting anticholinergic agent, blocks muscarinic M1 receptors to restore the dopamine-acetylcholine balance in the basal ganglia, preventing extrapyramidal symptoms (acute dystonia, parkinsonian rigidity, tremors, akathisia). Indicated for schizophrenia, schizoaffective disorder, and severe psychotic agitation complicated by high extrapyramidal risk.

Risperidone and Trihexyphenidyl (Benzhexol) is a therapeutic combination designed to provide antipsychotic efficacy while preventing drug-induced movement disorders. Risperidone, a benzisoxazole atypical antipsychotic, blocks dopamine D2 and serotonin 5-HT2A receptors to control psychosis, while trihexyphenidyl, a centrally acting anticholinergic agent, blocks muscarinic M1 receptors to restore the dopamine-acetylcholine balance in the basal ganglia, preventing extrapyramidal symptoms (acute dystonia, parkinsonian rigidity, tremors, akathisia). Indicated for schizophrenia, schizoaffective disorder, and severe psychotic agitation complicated by high extrapyramidal risk.

Rivastigmine is a pseudo-irreversible carbamate dual inhibitor of both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) on the WHO Model List of Essential Medicines. It facilitates cholinergic transmission by delaying acetylcholine degradation, with dual enzyme inhibition providing sustained efficacy in advanced disease where BuChE activity increases. Indicated for mild-to-moderate dementia of the Alzheimer's type and mild-to-moderate dementia associated with Parkinson's disease.

Rivastigmine is a pseudo-irreversible carbamate dual inhibitor of both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) on the WHO Model List of Essential Medicines. It facilitates cholinergic transmission by delaying acetylcholine degradation, with dual enzyme inhibition providing sustained efficacy in advanced disease where BuChE activity increases. Indicated for mild-to-moderate dementia of the Alzheimer's type and mild-to-moderate dementia associated with Parkinson's disease.

Rivastigmine is a pseudo-irreversible carbamate dual inhibitor of both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) on the WHO Model List of Essential Medicines. It facilitates cholinergic transmission by delaying acetylcholine degradation, with dual enzyme inhibition providing sustained efficacy in advanced disease where BuChE activity increases. Indicated for mild-to-moderate dementia of the Alzheimer's type and mild-to-moderate dementia associated with Parkinson's disease.

Rivastigmine is a pseudo-irreversible carbamate dual inhibitor of both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) on the WHO Model List of Essential Medicines. It facilitates cholinergic transmission by delaying acetylcholine degradation, with dual enzyme inhibition providing sustained efficacy in advanced disease where BuChE activity increases. Indicated for mild-to-moderate dementia of the Alzheimer's type and mild-to-moderate dementia associated with Parkinson's disease.

Rivastigmine is a pseudo-irreversible carbamate dual inhibitor of both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) on the WHO Model List of Essential Medicines. It facilitates cholinergic transmission by delaying acetylcholine degradation, with dual enzyme inhibition providing sustained efficacy in advanced disease where BuChE activity increases. Indicated for mild-to-moderate dementia of the Alzheimer's type and mild-to-moderate dementia associated with Parkinson's disease.

Rivastigmine is a pseudo-irreversible carbamate dual inhibitor of both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) on the WHO Model List of Essential Medicines. It facilitates cholinergic transmission by delaying acetylcholine degradation, with dual enzyme inhibition providing sustained efficacy in advanced disease where BuChE activity increases. Indicated for mild-to-moderate dementia of the Alzheimer's type and mild-to-moderate dementia associated with Parkinson's disease.

Rivastigmine is a pseudo-irreversible carbamate dual inhibitor of both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) on the WHO Model List of Essential Medicines. It facilitates cholinergic transmission by delaying acetylcholine degradation, with dual enzyme inhibition providing sustained efficacy in advanced disease where BuChE activity increases. Indicated for mild-to-moderate dementia of the Alzheimer's type and mild-to-moderate dementia associated with Parkinson's disease.

Rizatriptan Benzoate is a second-generation selective serotonin 5-HT1B and 5-HT1D receptor agonist with rapid oral absorption (onset of pain relief within 30 minutes). It selectively constricts painfully distended cranial vessels and inhibits trigeminal calcitonin gene-related peptide (CGRP) release. Indicated for the acute treatment of migraine with or without aura in adults.

Rizatriptan Benzoate is a second-generation selective serotonin 5-HT1B and 5-HT1D receptor agonist with rapid oral absorption (onset of pain relief within 30 minutes). It selectively constricts painfully distended cranial vessels and inhibits trigeminal calcitonin gene-related peptide (CGRP) release. Indicated for the acute treatment of migraine with or without aura in adults.

Trazodone Hydrochloride is a triazolopyridine serotonin antagonist and reuptake inhibitor (SARI). At therapeutic doses, it acts as a potent antagonist at postsynaptic 5-HT2A receptors and an antagonist at alpha-1 adrenergic and histamine H1 receptors, with weak inhibition of serotonin reuptake. Indicated for major depressive disorder with comorbid anxiety or insomnia, and widely used off-label as a non-habit-forming sleep aid in depression.

Trazodone Hydrochloride is a triazolopyridine serotonin antagonist and reuptake inhibitor (SARI). At therapeutic doses, it acts as a potent antagonist at postsynaptic 5-HT2A receptors and an antagonist at alpha-1 adrenergic and histamine H1 receptors, with weak inhibition of serotonin reuptake. Indicated for major depressive disorder with comorbid anxiety or insomnia, and widely used off-label as a non-habit-forming sleep aid in depression.

Zolpidem Tartrate is an imidazopyridine non-benzodiazepine hypnotic agent. It binds selectively with high affinity to the alpha-1 subunit-containing GABAA receptor subtype (omega-1 receptor) in the brain, sparing alpha-2 and alpha-3 subunits, resulting in potent sleep-inducing action with minimal myorelaxant and anticonvulsant effects. Indicated for short-term treatment of insomnia characterized by difficulties with sleep initiation.

Atomoxetine Hydrochloride is a selective norepinephrine reuptake inhibitor (NRI) without psychostimulant properties. It selectively blocks the presynaptic norepinephrine transporter (NET) in the prefrontal cortex, elevating both norepinephrine and dopamine locally without altering dopamine in the nucleus accumbens, conferring therapeutic ADHD benefits with zero abuse liability. Indicated for Attention Deficit Hyperactivity Disorder (ADHD) in children, adolescents, and adults.

Buspirone Hydrochloride is an azaspirodecanedione anxiolytic agent that acts as a high-affinity partial agonist at presynaptic and postsynaptic serotonin 5-HT1A receptors, with moderate affinity for dopamine D2 autoreceptors. Unlike benzodiazepines, it possesses zero affinity for GABAA receptors, producing effective sustained anxiolysis without causing sedation, cognitive impairment, muscle relaxation, anticonvulsant activity, or physical dependence and withdrawal. Indicated for generalized anxiety disorder (GAD) and short-term relief of anxiety symptoms.

Buspirone Hydrochloride is an azaspirodecanedione anxiolytic agent that acts as a high-affinity partial agonist at presynaptic and postsynaptic serotonin 5-HT1A receptors, with moderate affinity for dopamine D2 autoreceptors. Unlike benzodiazepines, it possesses zero affinity for GABAA receptors, producing effective sustained anxiolysis without causing sedation, cognitive impairment, muscle relaxation, anticonvulsant activity, or physical dependence and withdrawal. Indicated for generalized anxiety disorder (GAD) and short-term relief of anxiety symptoms.

Clonazepam and Propranolol is a psychotropic and autonomic regulator combination. Clonazepam provides sustained central anxiolysis and neuronal stabilization via GABAA chloride conductance, while propranolol blocks peripheral beta-adrenergic receptors, stopping autonomic hyperarousal (tremors, racing heartbeat, flushing). Indicated for social phobia, severe panic attacks, stage fright, and anxiety disorders characterized by palpitations and tremor.

Clonazepam and Propranolol is a psychotropic and autonomic regulator combination. Clonazepam provides sustained central anxiolysis and neuronal stabilization via GABAA chloride conductance, while propranolol blocks peripheral beta-adrenergic receptors, stopping autonomic hyperarousal (tremors, racing heartbeat, flushing). Indicated for social phobia, severe panic attacks, stage fright, and anxiety disorders characterized by palpitations and tremor.

Clonazepam and Propranolol is a psychotropic and autonomic regulator combination. Clonazepam provides sustained central anxiolysis and neuronal stabilization via GABAA chloride conductance, while propranolol blocks peripheral beta-adrenergic receptors, stopping autonomic hyperarousal (tremors, racing heartbeat, flushing). Indicated for social phobia, severe panic attacks, stage fright, and anxiety disorders characterized by palpitations and tremor.

Fluoxetine Hydrochloride is a prototype selective serotonin reuptake inhibitor (SSRI) on the WHO Model List of Essential Medicines. It blocks the presynaptic serotonin transporter (SERT) and possesses a long elimination half-life (1-3 days for parent drug, 7-15 days for active norfluoxetine), providing a built-in buffer against abrupt discontinuation syndrome. Also displays mild 5-HT2C antagonism, contributing to energizing/activating effects. Indicated for major depressive disorder, obsessive-compulsive disorder (OCD), bulimia nervosa, and panic disorder.

Fluoxetine Hydrochloride is a prototype selective serotonin reuptake inhibitor (SSRI) on the WHO Model List of Essential Medicines. It blocks the presynaptic serotonin transporter (SERT) and possesses a long elimination half-life (1-3 days for parent drug, 7-15 days for active norfluoxetine), providing a built-in buffer against abrupt discontinuation syndrome. Also displays mild 5-HT2C antagonism, contributing to energizing/activating effects. Indicated for major depressive disorder, obsessive-compulsive disorder (OCD), bulimia nervosa, and panic disorder.

Diazepam and Imipramine combines a classical long-acting benzodiazepine with a tricyclic antidepressant (TCA). Imipramine blocks reuptake of norepinephrine and serotonin to treat depression, while diazepam immediately quells panic, anxiety, motor agitation, and insomnia. Indicated for depression accompanied by pronounced anxiety, agitation, or sleep architecture disruption.

Diazepam and Imipramine combines a classical long-acting benzodiazepine with a tricyclic antidepressant (TCA). Imipramine blocks reuptake of norepinephrine and serotonin to treat depression, while diazepam immediately quells panic, anxiety, motor agitation, and insomnia. Indicated for depression accompanied by pronounced anxiety, agitation, or sleep architecture disruption.

Levetiracetam is a pyrrolidone derivative second-generation antiepileptic on the WHO Model List of Essential Medicines. It exhibits a unique mechanism of action, binding stereoselectively to synaptic vesicle protein 2A (SV2A) in presynaptic terminals, modulating exocytosis and restraining pathological vesicle release of excitatory neurotransmitters without affecting normal neurotransmission. Demonstrates near 100% oral bioavailability and minimal hepatic CYP450 metabolism. Indicated as monotherapy and adjunctive therapy for focal seizures, myoclonic seizures in juvenile myoclonic epilepsy, and primary generalized tonic-clonic seizures.

Zolpidem and Melatonin is a dual-mechanism sleep regulator combining a non-benzodiazepine positive allosteric modulator with the endogenous pineal chronobiotic hormone. Zolpidem binds selectively to the alpha-1 subunit of the GABAA receptor, rapidly inducing sleep onset within 15-30 minutes, while melatonin acts on MT1 and MT2 receptors in the suprachiasmatic nucleus to synchronize circadian sleep architecture and promote restful sleep maintenance. Indicated for short-term management of sleep-onset and sleep-maintenance insomnia and jet lag/circadian rhythm sleep disorders.

Zolpidem and Melatonin is a dual-mechanism sleep regulator combining a non-benzodiazepine positive allosteric modulator with the endogenous pineal chronobiotic hormone. Zolpidem binds selectively to the alpha-1 subunit of the GABAA receptor, rapidly inducing sleep onset within 15-30 minutes, while melatonin acts on MT1 and MT2 receptors in the suprachiasmatic nucleus to synchronize circadian sleep architecture and promote restful sleep maintenance. Indicated for short-term management of sleep-onset and sleep-maintenance insomnia and jet lag/circadian rhythm sleep disorders.

Methylphenidate Hydrochloride is a central nervous system stimulant on the WHO Model List of Essential Medicines. It acts by blocking the presynaptic dopamine transporter (DAT) and norepinephrine transporter (NET), substantially inhibiting reuptake and boosting synaptic catecholamine availability in the prefrontal cortex, enhancing sustained attention, impulse inhibition, and executive control. Indicated for Attention Deficit Hyperactivity Disorder (ADHD) and narcolepsy.

Methylphenidate Hydrochloride is a central nervous system stimulant on the WHO Model List of Essential Medicines. It acts by blocking the presynaptic dopamine transporter (DAT) and norepinephrine transporter (NET), substantially inhibiting reuptake and boosting synaptic catecholamine availability in the prefrontal cortex, enhancing sustained attention, impulse inhibition, and executive control. Indicated for Attention Deficit Hyperactivity Disorder (ADHD) and narcolepsy.

Methylphenidate Hydrochloride is a central nervous system stimulant on the WHO Model List of Essential Medicines. It acts by blocking the presynaptic dopamine transporter (DAT) and norepinephrine transporter (NET), substantially inhibiting reuptake and boosting synaptic catecholamine availability in the prefrontal cortex, enhancing sustained attention, impulse inhibition, and executive control. Indicated for Attention Deficit Hyperactivity Disorder (ADHD) and narcolepsy.

Methylphenidate Hydrochloride is a central nervous system stimulant on the WHO Model List of Essential Medicines. It acts by blocking the presynaptic dopamine transporter (DAT) and norepinephrine transporter (NET), substantially inhibiting reuptake and boosting synaptic catecholamine availability in the prefrontal cortex, enhancing sustained attention, impulse inhibition, and executive control. Indicated for Attention Deficit Hyperactivity Disorder (ADHD) and narcolepsy.

Naltrexone Hydrochloride is a pure, long-acting competitive opioid receptor antagonist on the WHO Model List of Essential Medicines. It competitively binds to mu, kappa, and delta opioid receptors in the brain, completely blocking the subjective euphoric and rewarding effects of exogenous opioids and diminishing alcohol craving by blocking endogenous opioid release triggered by alcohol consumption. Indicated for the treatment of alcohol dependence and prevention of relapse in opioid dependence following comprehensive detoxification.

Opipramol is a tricyclic psychotropic agent that acts uniquely as a high-affinity sigma-1 and sigma-2 receptor agonist, with low-to-moderate affinity for dopamine D2, 5-HT2, and H1 receptors, and no monoamine reuptake inhibition. Produces prominent anxiolytic, calming, and somatic symptom-stabilizing effects. Indicated for generalized anxiety disorder (GAD) and somatoform disorders.

Opipramol is a tricyclic psychotropic agent that acts uniquely as a high-affinity sigma-1 and sigma-2 receptor agonist, with low-to-moderate affinity for dopamine D2, 5-HT2, and H1 receptors, and no monoamine reuptake inhibition. Produces prominent anxiolytic, calming, and somatic symptom-stabilizing effects. Indicated for generalized anxiety disorder (GAD) and somatoform disorders.

Perampanel is a first-in-class, highly selective, non-competitive antagonist at postsynaptic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptors on excitatory neurons. By targeting the primary mediator of fast excitatory synaptic transmission in the brain, it halts seizure propagation. Indicated as adjunctive therapy for partial-onset seizures and primary generalized tonic-clonic seizures.

Perampanel is a first-in-class, highly selective, non-competitive antagonist at postsynaptic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptors on excitatory neurons. By targeting the primary mediator of fast excitatory synaptic transmission in the brain, it halts seizure propagation. Indicated as adjunctive therapy for partial-onset seizures and primary generalized tonic-clonic seizures.

Safinamide is a multimodal agent with dual mechanisms of action: potent, selective, and reversible inhibition of monoamine oxidase B (MAO-B), combined with state- and use-dependent blockade of voltage-gated sodium channels and inhibition of stimulated glutamate release. Indicated as add-on therapy to a stable dose of levodopa/carbidopa in Parkinson's disease patients experiencing "off" episodes.

Tianeptine is an atypical psychotropic agent with neuroprotective and glutamatergic modulating actions. In contrast to classical antidepressants, it acts as a full agonist at the mu-opioid receptor (MOR) and modulates AMPA/NMDA glutamate receptor phosphorylation in the hippocampus and amygdala, reversing stress-induced dendritic atrophy. Indicated for mild, moderate, or severe depressive episodes, dysthymia, and anxiety associated with somatic disorders.

Tofisopam is a 2,3-benzodiazepine derivative that differs structurally and pharmacologically from classical 1,4-benzodiazepines. It binds to stereospecific sites in the central nervous system without binding to classical benzodiazepine GABAA binding sites, producing anxiolytic and autonomic stabilizing actions without causing sedation, muscle relaxation, amnesia, motor impairment, or dependence. Indicated for anxiety disorders, somatic neuroses, vegetative dystonia, and alcohol withdrawal anxiety.

Trifluoperazine is a high-potency piperazine phenothiazine typical antipsychotic. It potently blocks postsynaptic dopamine D2 receptors in the mesolimbic and nigrostriatal systems, producing robust anti-hallucinatory and anti-delusional effects with low sedation and low autonomic burden, but high propensity for extrapyramidal movement disorders. Indicated for schizophrenia, other psychotic disorders, and short-term non-psychotic anxiety.

Trifluoperazine is a high-potency piperazine phenothiazine typical antipsychotic. It potently blocks postsynaptic dopamine D2 receptors in the mesolimbic and nigrostriatal systems, producing robust anti-hallucinatory and anti-delusional effects with low sedation and low autonomic burden, but high propensity for extrapyramidal movement disorders. Indicated for schizophrenia, other psychotic disorders, and short-term non-psychotic anxiety.

Levetiracetam is a pyrrolidone derivative second-generation antiepileptic on the WHO Model List of Essential Medicines. It exhibits a unique mechanism of action, binding stereoselectively to synaptic vesicle protein 2A (SV2A) in presynaptic terminals, modulating exocytosis and restraining pathological vesicle release of excitatory neurotransmitters without affecting normal neurotransmission. Demonstrates near 100% oral bioavailability and minimal hepatic CYP450 metabolism. Indicated as monotherapy and adjunctive therapy for focal seizures, myoclonic seizures in juvenile myoclonic epilepsy, and primary generalized tonic-clonic seizures.

Levetiracetam is a pyrrolidone derivative second-generation antiepileptic on the WHO Model List of Essential Medicines. It exhibits a unique mechanism of action, binding stereoselectively to synaptic vesicle protein 2A (SV2A) in presynaptic terminals, modulating exocytosis and restraining pathological vesicle release of excitatory neurotransmitters without affecting normal neurotransmission. Demonstrates near 100% oral bioavailability and minimal hepatic CYP450 metabolism. Indicated as monotherapy and adjunctive therapy for focal seizures, myoclonic seizures in juvenile myoclonic epilepsy, and primary generalized tonic-clonic seizures.

Phenobarbitone (Phenobarbital) is a long-acting barbiturate anticonvulsant on the WHO Model List of Essential Medicines. It binds allosterically to GABAA receptors, prolonging the open duration of neuronal chloride ion channels, enhancing GABA-mediated inhibition, and suppressing glutamate-mediated excitation. Indicated for generalized tonic-clonic seizures, focal seizures, and neonatal seizures.

Phenobarbitone (Phenobarbital) is a long-acting barbiturate anticonvulsant on the WHO Model List of Essential Medicines. It binds allosterically to GABAA receptors, prolonging the open duration of neuronal chloride ion channels, enhancing GABA-mediated inhibition, and suppressing glutamate-mediated excitation. Indicated for generalized tonic-clonic seizures, focal seizures, and neonatal seizures.

Sumatriptan is a pioneer selective 5-HT1B/1D receptor agonist (triptan) on the WHO Model List of Essential Medicines. Activation of vascular 5-HT1B receptors mediates vasoconstriction of painfully dilated dural and meningeal blood vessels, while stimulation of neuronal 5-HT1D receptors on trigeminal perivascular nerves inhibits the release of pro-inflammatory neuropeptides (CGRP, substance P). Indicated for the acute abortive treatment of migraine attacks with or without aura in adults.